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Chronic  inflammation  in  the  brain  results  in  the  development  of  several  CNS 
diseases,  including Alzheimer’s and Parkinson’s diseases, multiple sclerosis,  and tumors. 
IL-1, a pro-inflammatory cytokine released by activated microglia and astrocytes, instigates 
the  expression  of  factors  promoting  the  progression  of  these  CNS  disorders,  including 
cytokines,  chemokines,  and  components  of  matrix  remodeling  systems,  such  as  the 
plasminogen activator system. IL-1 also increases the mRNA expression and activity of 
SphK, the enzyme that phosphorylates Sph to form S1P, a bio-active sphingolipid.  This 
vi
vii
thesis demonstrates that IL-1 and S1P enhance the mRNA and protein expression of PAI-1 
and uPAR, two key components of the plasminogen activator system, in glioblastoma cells. 
The S1P-induced mRNA expression of PAI-1 and uPAR is mediated by the S1P2 receptor, 
and requires Rho-kinase and MEK1. However, IL-1 regulation of PAI-1 and uPAR mRNA 
expression is independent of SphK, and thus S1P. IL-1- and S1P-induced mRNA expression 
of PAI-1 and uPAR results in the increased  in vitro invasion of glioblastoma cells. Since 
significant amounts of IL-1 are secreted from gliomas, and it increases the production of S1P 
via inciting the activity and mRNA expression of SphK, we propose a mechanism by which 
S1P and IL-1 influence the invasion of glioblastoma cells  by increasing the mRNA and 
protein expression of uPAR and PAI-1. 
IL-1 and S1P also influence the mRNA expression of chemokines implicated in the 
development and progression of multiple sclerosis, namely IP-10 and RANTES, in primary 
human astrocytes.  IP-10 and RANTES attract  T cells,  which are  the major pathological 
cause of  multiple  sclerosis.  This  thesis  demonstrates  a  novel  mechanism by which S1P 
significantly  inhibits  the  IL-1-induced  mRNA  expression  of  these  chemokines.  The 
mechanism by which S1P reduces  IL-1-induced IP-10 and RANTES mRNA expression 
involves the prolonged hyperphosphorylation of TAK1, as well as the inhibition of IL-1-
stimulated IFNβ production and the phosphorylation of STAT1 and STAT2. 
In  summary,  this  dissertation describes  the mechanisms by which  S1P and IL-1 
control the mRNA expression of two chemokines associated with multiple sclerosis, and the 
components  of  the plasminogen activator  system,  which  are  critical  for  the  invasion  of 
glioblastoma cells; thus, indicating future therapeutic targets for destructive CNS disorders. 
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CHAPTER 1 
INTRODUCTION
1.1 Inflammation in the Brain
Inflammation is the classic response of the human body to injury and infection. In 
most  tissues,  inflammation  is  characterized  by  swelling,  redness,  pain,  and  heat.  This 
characteristic phenotype of inflammation is caused by immune cells, such as macrophages 
and leukocytes that invade the inflamed tissue. Once activated, macrophages are the primary 
source  of  cytokines  and  growth  factors,  which  then  influence  proliferation,  migration, 
angiogenesis, etc. in order to repair the affected tissue . 
Although the brain was once considered immune deficient, as it lacks a lymphatic 
system and is protected by the blood brain barrier (BBB), it is now known that this is not the 
case. However, its immune response is unarguably different from that in other tissues. For 
example, swelling, which is typical in inflammation, is limited by the cranium and can lead 
to intracranial pressure and death. Also, compared to other tissues, leukocyte recruitment is 
delayed in the brain. However, once an insult on the brain occurs, pro-inflammatory factors 
are rapidly released from microglia (the immune cells of the brain) , and activated microglia 
undergo  a  morphological  change  from ramified  microglia  into  amoeboid  microglia  [2]. 
Activated microglia release a variety of pro-inflammatory and likely cytotoxic factors, which 
then stimulate surrounding astrocytes to secrete additional pro-inflammatory cytokines and 
chemokines.  Cytokines  and  chemokines  are  then  responsible  for  the  recruitment  of 
1
2leukocytes and neutrophils. During acute inflammation this response is controlled, limited, 
and successful in repairing the damaged tissue. However, chronic inflammation, which is un-
controlled and sustained inflammation, can often result in tissue damage and necrosis. 
Chronic  inflammation  has  been  linked  to  traumatic  brain  injury,  various  central 
nervous system (CNS) disorders  (Alzheimer’s,  Multiple  Sclerosis,  and HIV-1 associated 
dementia),  and even cancer  .  In  fact,  in  Alzheimer’s  disease,  which is  characterized  by 
progressive  neuronal  damage caused by the neurotoxicity  of  the  β-amyloid  peptide,  the 
microglial reaction to β-amyloid  and the plaques  can be deleterious to neurons. β-amyloid 
peptide recruits and activates microglia , thus leading to the release of neurotoxic factors, 
such as NO , TNFα , and superoxide . Activated microglia have also been implicated in the 
progression of HIV-associated dementia, as HIV enters the brain via circulating monocytes 
and is  then collected  by microglia  .  Therefore,  the microglia  act  as  a  factory  for  viral 
replication, leading to an increase in pro-inflammatory factors  and the progression of the 
disease. Moreover, activated microglia have been associated with Parkinson’s disease and 
Multiple Sclerosis (MS) . Interestingly, viral infection with the Epstein-Barr virus has been 
connected  to  MS,  as  EBV-infected  cells  were  found  in  the  meninges  and  perivascular 
immune infiltrates of active white matter lesions in almost 100% of the analyzed MS patients 
. 
Just as chronic inflammation in the brain can lead to various CNS diseases, chronic 
inflammation  of  other  tissues  present  in  the  body  has  been  shown  to  stimulate  the 
progression of several types of cancer. In fact, the tumor microenvironment, which consists 
of  macrophages,  dendritic  cells,  T cells,  and natural  killer  cells,  which  all  produce  and 
3secrete a variety of cytokines, reactive oxygen species, serine and cysteine proteases, and 
MMPs, has been shown to advance tumor promotion and progression via mouse models of 
human cancer . Interestingly, chronic inflammation may be a key factor in transformation, as 
infection with  Helicobacter pylori is linked to gastrointestinal carcinogenesis; Hepatitis B 
infection is associated with hepatocellular carcinoma; cigarette smoking with lung cancer; 
Schistosomiasis is connected with bladder carcinoma; alcoholism with pancreatic cancer ; 
and inflammatory bowel diseases is strongly correlated with colon carcinogenesis . So while 
inflammation is a necessary component of  the immune response to clear infection or repair 
tissue, if inflammation persists it can become detrimental to the affected tissue and the host, 
as it may lead to cancer or various other CNS diseases. 
1.2 Interleukin-1
As mentioned previously, the tumor microenvironment, which consists of a variety 
of immune cells, contributes to tumor progression by supplying an array of cytokines and 
chemokines to neighboring tumor cells. In addition, tumor cells are capable of contributing 
to their microenvironment as well. In fact, gliomas, the most common and most malignant of 
the primary brain tumors,  have been shown secrete  substantial  amounts of interleukin-1 
(IL-1) . IL-1 is the predominant pro-inflammatory cytokine in the brain, is a 17 kilodalton 
(kDa) polypeptide, and exists in two isoforms, IL-1α and IL-1β . Although, IL-1α and IL-1β 
share 30% sequence homology, bind to the same receptor, and activate the same signaling 
pathways, they are expressed and secreted differently . For instance, IL-1α is only located 
within the cell, while IL-1β is secreted upon cleavage of pro-IL-1β by caspase-1 . In contrast 
4to pro-IL-1β which must be cleaved in order to be active, pro-IL-1α is equally active as its 
mature form. 
Regardless of the isoform, all known functions of IL-1 are due to the interaction with 
their receptor IL-1R . The IL-1R is a member of the Toll-like receptor family, specifically 
the TIR (Toll-IL-1 receptor)  superfamily  .  Members  of  the TIR superfamily  contain  an 
intracellular  TIR domain,  which  can  interact  with  the adaptor  protein  MyD88 (myeloid 
differentiation factor 88) upon stimulation . Downstream signaling from IL-1R also requires 
the association of an accessory protein, called IL-1RAcP, in order to activate nuclear factor 
kappa B (NF-κB) and the mitogen-activated protein (MAP) kinase pathways, including p38 
MAPK, c-jun N-terminal kinase (JNK), and extracellular-signal regulated kinase (ERK1/2) . 
Upon stimulation with IL-1, the IL-1RI sequesters the MyD88 adapter molecule , 
which then recruits IRAK4 (IL-1 receptor associated kinase 4), IRAK, and TRAF6 (TNF 
receptor associated factor 6). Once this complex is formed, IRAK4  is activated, thus leading 
to the hyperphosphorylation of IRAK  and the interaction with Pellino 1 . This complex is 
then  released  from the  receptor  to  form and intermediate  complex,  upon  which  TAK1 
(transforming growth factor  β-activated kinase, a MAP3K), TAB2 (TAK1-binding protein 
2), and TAB3 all bind and are phosphorylated at the membrane . Once IRAK is ubiquitinated 
and degraded, the TRAF6-TAK1-TAB2-TAB3 complex moves from the membrane to the 
cytosol. Once in the cytosol, TAK1 becomes phosphorylated, activated, induces IκB kinase 
(inhibitor of NF-κB kinase, IKK), which leads to the phosphorylation/degradation of IκBs 
(inhibitor of NF-κB) and activation NF-κB  (Figure 1.1, ). However, TAK1 is also capable 
5of  activating  p38  and  JNK  via  MKK3/6  and  MKK4/7,  respectively  (Figure  1.1). 
Additionally,  IL-1  can  activate  a  TAK1-independent  and  MEKK3-dependent  pathway 
(Figure 1.1) . The difference in the two pathways is that the TAK1-dependent pathway leads 
to IKKα/β phosphorylation and IKKβ activation, and thus classical NF-κB activation via 
IκBα phosphorylation and degradation; while the MEKK3-dependent pathway stimulates 
IKKγ phosphorylation, IKKα activation, and NF-κB activation by IκBα phosphorylation 
and  dissociation.  Both  pathways  are  controlled  at  the  point  of  IRAK  modification  . 
Specifically, a point mutation in IRAK from lysine 134 to arginine (K134R) eliminated IL-1-
induced ubiquitination and degradation, which ablated TAK1-dependent NF-κB activation, 
but  not  MEKK3-dependent  activation  of  NF-κB .  Pellino  proteins  are  the E3 ubiquitin 
ligases responsible for IRAK ubiquitination, of which there are four (Pellino1, 2, 3a, and 3b). 
Pellino 1 and 2 mediated IRAK modification leads to the activation NF-κB, whereas Pellino 
3a and 3b leads to JNK activation . 
6Figure 1.1 Model depicting TAK1-dependent and TAK1-independent IL-1 signaling. 
IL-1 stimulation results in MyD88 and Tollip recruitment to the IL-1 receptor. Subsequently, 
IRAK4, IRAK, and TRAF6 are recruited, which leads to the arrangement of complex I. At 
this  point,  IRAK4  is  activated,  IRAK is  hyperphosphorylated,  and  this  allows  for  the 
interaction  of  Pellino  1/2  with  IRAK4-IRAK-TRAF6  complex  (intermediate  complex). 
IRAK is ubiquitinated at Lys-63, which induces the interaction of the intermediate complex 
(Pellino  2-IRAK4-IRAK-TRAF6  with  membrane  bound  TAK1-TAB1-TAB2  (which 
completes  the  formation  of  complex  II).  An  unknown  E3  protein  induces  the  Lys-48 
ubiquitination of IRAK, causing the degradation of IRAK, which leads to the translocation 
of TRAF6-TAK1-TAB1-TAB2 (complex III) to the cytosol from the membrane. TAK1 is 
activated and eventually leads to the activation of NF-κB, JNK, and p38. In contrast the 
TAK1-independent  pathway  involves  MEKK3  induction  of  IKKγ phosphorylation  and 
IKKα activation, which leads only to the activation of NF-κB. 
7Modified from 
8In the healthy adult brain IL-1 and the IL-1R are expressed at very low levels, and 
IL-1 is suspected to regulate long-term potentiation, sleep, and memory . However, during 
pathological conditions, such as CNS injury  and focal cerebral ischemia , levels of IL-1 are 
increased substantially. Furthermore,  in vitro studies in astrocytes have revealed that IL-1 
induces proliferation , astrogliosis , and activates NF-κB, p38, JNK, and ERK1/2 (Reviewed 
in ). Additionally, IL-1 stimulation leads to the expression of cytokines, such as IL-6, IL-8, 
and TNF-α, chemokines, including MIP-1α, MIP-1β, MCP-1, IP-10, and RANTES (Chapter 
3),  growth  factors,  consisting  of  bFGF,  NGF,  VEGF,  and  PDGF,  and  matrix 
metalloproteinases,  specifically  MMP9 .  Moreover,  we show that  IL-1 can increase two 
critical  components  of  the  plasminogen  activator  system  (urokinase  protease  activator 
receptor [uPAR] and plasminogen activator inhibitor-1 [PAI-1]) in U373 glioblastoma cells, 
thus contributing to their invasive phenotype (Chapter 2).
In  addition  to  its  robust  acute  effects,  IL-1  has  been  involved  in  chronic  CNS 
disorders. In the brains’ of patients with Alzheimer’s disease and Down’s syndrome, IL-1β 
has been found to increase the supply and processing of the β-amyloid precursor protein, in 
addition to the production of other known plaque-associated proteins . Additionally, IL-1 
levels  were  elevated  in  the  lesions  of  human  immunodeficiency virus  (HIV)-associated 
dementia patients , and in the spinal fluid and demyelinated lesions of multiple sclerosis 
patients . These results suggest that IL-1 is critical for both acute and chronic inflammation, 
and thus that  IL-1 may play a significant  role  in  the progression of  many neurological 
diseases.
91.3 Chemokines
Additionally, IL-1, when released from activated microglia, stimulates surrounding 
astrocytes to produce and secrete a variety of cytokines (including IL-1) and chemokines. 
This triggers leukocytes, which under normal physiological conditions are constantly in the 
blood stream surveying the body for signs of injury or infection,  to invade the vascular 
endothelium and follow the chemotactic gradient of chemokines into the inflamed tissue . 
The chemokine family consists of approximately 50 small secreted ligands (8-13 kDa) that 
bind  to  20 different  G-protein-coupled  seven-transmembrane receptors  .  The  chemokine 
family is divided into two subfamilies, CXC and CC chemokines, based on the absence or 
presence of an amino acid between the first two NH2-terminal cysteines . The CXC family of 
chemokines is further separated based on whether or not they contain the ELR (Glu-Leu-
Arg)  motif.  ELR+CXC  chemokines  (CXCL1-8)  are  chemotatic  for  neutrophils  and  are 
angiogenic, while ELR-CXC chemokines (CXCL9-12) attract mononuclear leukocytes and 
are  angiostatic.  For  example,  over-expression  of  CXCL10  (IP-10,  interferon-γ-inducible 
protein-10) in a human lymphoma mouse model, as well as in a human non-small cell lung 
cancer SCID mouse model , resulted in spontaneous regression due to deficient angiogenesis 
. In contrast, IL-8 (interleukin-8), a member (CXCL8) of the CXC family of chemokines, 
attracts neutrophils and is ELR+; thus IL-8 is pro-angiogenic and has been associated with 
increased microvessel counts in uterine cervical cancers . Meanwhile, CC chemokines, such 
as CCL5 (RANTES, regulated on activation normal T-cell-expressed and secreted), CCL3 
(MIP-1α, macrophage  inflammatory  protein-1α),  and  CCL4  (MIP-1β, macrophage 
inflammatory  protein-1β),  attract  an  array  of  leukocytes.  For  instance,  RANTES  is 
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chemotactic for T cells, while CCL2 (MCP-1, monocyte chemoattractant protein-1) attracts 
monocytes. 
In order for chemokines to exert their effects, they must interact with their receptors. 
The chemokine receptors are  separated into CXCR1-6, CCR1-11,  CX3CR1,  and XCR1. 
Some of the receptors are highly promiscuous, while others have a high specificity for their 
ligands. Examples of monogamous receptor-ligand interactions are CXCL12 binding to the 
CXCR4 receptor, fractalkine binding to the CX3CR1 receptor, and lymphotactin binding to 
the  XCR1 receptor.  In  contrast,  IP-10,  CXCL9,  and CXCL11 can  all  interact  with  the 
CXCR3 receptor. However, it is not just the receptors that are promiscuous in this system, as 
some ligands can also interact with multiple receptors. For instance, RANTES can bind to 
CCR1, CCR3, or CCR5 . For a complete list of the chemokine ligands and their receptors, 
please see Table 1.1 (Modified from ). 
Chemokines  are  involved  in  a  multitude  of  processes,  including  angiogenesis, 
hematopoiesis, and tumor progression and metastasis . Indeed, the chemokine CXCL12 and 
its receptor CXCR4, as well as CXCL1, are upregulated in primary brain tumors, such as 
glioblastoma,  astrocytoma,  and  medulloblastomas  .  Moreover,  this  chemokine  and  its 
receptor  have  been  shown to  be  crucial  for  the  development  of  the  CNS.  Specifically, 
CXCR4  signaling  is  necessary  for  neuronal  precursor  migration,  axon  guidance,  and 
maintenance  of  neural  progenitor  cells  .  Meanwhile,  CXCL12  regulates  neurotoxicity, 
neurotransmission, and neuroglial interactions . Other chemokines, such as RANTES and 
MCP-1, were 
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Table 1.1 Table of Chemokines and their respective receptors. Chemokines are divided 
into two classes, CXC and CC. They are listed along with their receptors, alternative names, 
as well as the cell types they attract. Tm, memory T cells; B, B cells; actT, activated T cell; 
Bs, basophil; T, resting T cell; Eo, eosinophil; NK, natural killer cells; Mo, monocyte; PMN, 
neutrophils; mDC, mature dendritic cells; iDC, immature dendritic cells. 
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Systematic Name Functional Name Responding Cell Known Receptor(s)
CXC Chemokines
CXCL1 Groα PMN CXCR2>CXCR1
CXCL2 Groβ PMN CXCR2
CXCL3 Groγ PMN CXCR2
CXCL4 PF4 Fibroblast
CXCL5 ENA-78 PMN CXCR2
CXCL6 GCP-2 PMN CXCR1, CXCR2
CXCL7 NAP-1 PMN CXCR1. CXCR2
CXCL8 IL-8 PMN CXCR1, CXCR2
CXCL9 MIG actT(TH1), NK CXCR3
CXCL10 IP-10 actT(TH1), NK CXCR3
CXCL11 I-TAC actT(TH1), NK CXCR3
CXCL12 SDF-1α/β All cell types CXCR4
CXCL13 BLC, BCA-1 B CXCR5
CXCL14 BRAK, Bolekine cAMP activated Mo
CXCL15 Human unknown PMN
CXCL16 actT CXCR6
CXCL17 DMC
CC Chemokines
CCL1 I-309 iDC, actT (TH2) CCR8
CCL2 MCP-1 Bs, Mo, actT, NK, 
iDC
CCR2
CCL3 MIP-1α Eo, Mo, actT, NK, 
iDC
CCR1. CCR5
CCL3L1 LD78β
CCL4 MIP-1β Mo, actT,(TH1), NK, 
iDC
CCR5
CCL4L1 AT744.2
CCL5 RANTES Eo, Bs, Mo, actT, 
NK, iDC
CCR1, CCR3, CCR5
CCL6 Human unknown Mo CCR1, CCR2, CCR3
CCL7 MCP-3 Eo, Bs, Mo, actT, CCR1, CCR2, CCR3
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NK, iDC
CCL8 MCP-2 Bs, Mo, actT, NK, 
iDC
CCR1, CCR2, 
CCR3, CCR5
CCL9/10 Human unknown PMN, actT CCR1
CCL11 Eotaxin Eo, Bs, actT(TH2), 
iDC
CCR3
CCL12 Human unknown Bs, Mo, actT, NK, 
iDC
CCR2
CCL13 MCP-4 Bs, Mo, actT, NK CCR1, CCR2, CCR3
CCL14 HCC-1 Eo, Mo CCR1
CCL15 HCC-2 PMN, Eo, Mo CCR1, CCR3
CCL16 HCC-4 LEC Mo, actT(TH1) CCR1
CCL17 TARC actT(TH2) CCR4
CCL18 PARC T, iDC
CCL19 MIP3β, ELC T, actT, mDC CCR7
CCL20 MIP3α, LARC Tm, B, iDC CCR6
CCL21 SLC T, actT, mDC CCR7
CCL22 MDC actT(TH2), iDC CCR4
CCL23 MPIF-1 PMN, Mo, T CCR1
CCL24 Eotaxin 2 Eo, Bs, actT(TH2), 
iDC
CCR3
CCL25 TECK Thymocytes, T CCR9
CCL26 Eotaxin 3 Eo, Bs, actT(TH2), 
iDC
CCR3
CCL27 CTACK, ILC act CCR10
CCL28 MEC act CCR10
Other Classes
XCL1 Lymphotaxin T XCR1
XCL2 SCM-1β T XCR1
CX3CL1 Fractalkine Mo, actT, NK CX3CR1
Modified from 
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discovered to increase the migration and differentiation of mouse embryonic dorsal  root 
ganglia cells . Additionally, IL-8 (CXCL8) and GROα control fast synaptic transmission, as 
well as long-term synaptic plasticity of the cerebellum  .
In  contrast,  during inflammatory  diseases  of  the CNS,  chemokines  play  a  much 
different role. Specifically,  they play a significant role in leukocyte trafficking, which is 
responsible for the pathology of the vast majority of CNS diseases. For instance, increased 
levels of IP-10 have been found in the cerebrospinal fluid of patients with multiple sclerosis , 
as  well  as  in  patients  with  HIV-associated  dementia  ,  where  IP-10  may  also  act  as  a 
neurotoxin  .  Moreover,  IP-10  expression  is  elevated  after  ischemia  and  brain  injury  . 
Interestingly, RANTES has also been linked to the progression of multiple sclerosis , and its 
expression has been inversely correlated with the progression of HIV-1 diseases .  More 
importantly, IL-1 signaling is a major regulator of these chemokines in human astrocytes , 
and it is for these reasons that these specific chemokines are further discussed in Chapter 3.
1.4 Sphingosine 1-phosphate
Interestingly, IL-1 is also capable of inducing sphingosine kinase (SphK) activation 
and expression , which is the enzyme responsible for producing sphingosine 1-phosphate 
(S1P) from sphingosine (Sph). There are two isoforms of SphK, SphK1 and SphK2. Their 
substrate Sph, which has been shown to be involved in cell cycle arrest and apoptosis , is 
converted into S1P via  phosphorylation on the 1-OH. In contrast  to Sph, S1P has been 
implicated in cell proliferation, survival, migration, angiogenesis, and differentiation . Thus, 
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the balance of these metabolites,  also known as the sphingolipid rheostat,  is  decisive in 
determining cell fate .
S1P can act both intracellularly as a second messenger, and extracellularly, in an 
autocrine/paracrine  manner,  by  binding  to  its  five  transmembrane  G-protein  coupled 
receptors (S1P1-5) . The individual S1P receptors can couple to a distinct group of G proteins, 
with varying affinities for different affecter molecules, which can lead to the activation of 
mitogen-actvated protein kinase (MAPK/ERK), phospholipase C (PLC), PI3K, Rac, Rho, 
and JNK (Reviewed in ). Thus, depending on the receptor expressed in a given cell type, S1P 
binding can activate various pathways with often opposing functions. For instance, the S1P1 
and S1P3 receptors have been shown to increase endothelial cell migration, while the S1P2 
receptor has been shown to inhibit endothelial and glioma cell migration . Conversely, the 
S1P2 receptor has recently been shown to increase the invasion of glioma cells . Although 
there is a multitude of information known about the extracellular signaling of S1P, it has also 
been established that intracellular S1P can increase DNA synthesis, and regulate apoptosis , 
differentiation  ,  calcium mobilization  ,  DNA synthesis  ,  and  inflammatory  responses  . 
However, the mechanism and the intracellular targets of S1P signaling are still unknown.
S1P is  abundantly stored in  blood platelets,  and can be found in  the blood at  a 
concentration of 0.4 to 1.5 µM ; therefore, it seems logical that S1P would play an important 
role  in  angiogenesis.  In  fact,  early  studies  in  human  umbilical  vein  endothelial  cells 
(HUVEC) demonstrated that in response to S1P, vascular endothelial  cells  migrated and 
subsequently morphed into capillary networks . More recently, it was shown that the binding 
of S1P to the S1P1 receptor increases the production of the pro-angiogenic growth factor, 
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VEGF .  Moreover,  S1P seems to  be  important  in  neural  and  vascular  development,  as 
SphK1/SphK2  double-knockout  mice  (which  are  deficient  in  S1P)  have  severe 
abnormalitites  in  neurogenesis,  neural  tube closure,  and angiogenesis,  thus is  embryonic 
lethal  .  Other  functions  in  the  brain  include,  regulating  neural  stem cell  or  progenitor 
migration toward the site of injury ,  inducing mouse embryonic astrocyte proliferation , 
acting as a neurotrophin-3 (NT-3) mediator of oligodendrocyte progenitor survival ,  and 
increasing the expression of glial cell line-derived neurotrophic factor (GDNF) to promote 
astrocyte proliferation .
Since S1P is pro-angiogeneic and anti-apoptotic, it is not surprising that S1P plays a 
significant role in cancer growth and progression. In fact, SphK1, and thus S1P, has been 
shown to be up-regulated in a variety of cancers . Recently, it was shown that a monoclonal 
antibody with a high affinity and specificity for S1P can slow tumor progression and related 
angiogenesis in several human cancer models, including lung, colon, breast, melanoma, and 
ovarian cancers . Moreover, the S1P receptor antagonist FTY720-P, when interacting with 
S1P  receptors  (all  except  S1P2),  potently  reduces  S1P  induced  angiogenesis  in  corneal 
models,  and reduced primary tumor and metastatic tumor growth in a melanoma mouse 
model . Conversely, S1P was shown to increase the chemotactic migration and invasion of 
esophageal adenocarcinoma cells  and OVCAR3 ovarian cancer cells , as well as the in vitro 
invasion of U373 glioblastoma cells (Chapter 2). Moreover, increased levels of expression of 
SphK1,  and  therefore  S1P,  have  been  correlated  to  decreased  survival  of  glioblastoma 
patients  .  Since  activation  of  SphK1  is  an  important  step  in  the  stimulation  of  the 
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plasminogen activator system in response to growth factors, such as EGF, we studied the 
effects of S1P on the plasminogen activator system (Chapter 2). 
1.5 Plasminogen Activator System
Glioblastoma multiforme (GBM) is one of the most common and most malignant 
tumors  of  the central  nervous system .  Their  invasive  phenotype is  partially  due to  the 
degradation of the extracellular matrix (ECM). The degradation of the ECM requires the 
activation of proteinases and the suppression of their inhibitors. ECM degradation typically 
involves two proteolytic systems: the plasminogen activator system (PAS), which controls 
the activation of plasmin from inactive plasminogen, and the matrix metalloproteinases and 
their inhibitors . 
In the brain, microglia are responsible for the production of inactive plasminogen, 
and astrocytes and glioma cells supply the components of the PAS, which produce active 
plasmin  from plasminogen.  Plasmin,  which  is  a  serine  protease  with  a  broad  range  of 
specificity,  is  activated  by  tissue  type  plasminogen  activator  (tPA)  and  urokinase-type 
plasminogen activator (uPA) .  tPA is  mainly involved in  the dissolution of fibrin  clots; 
whereas uPA, upon binding to its cell surface receptor (uPAR), has its own protease activity, 
and is important for localized ECM degradation that is necessary for cell  migration and 
invasion . Despite their different functions, both tPA and uPA are regulated by their specific 
inhibitors:  plasminogen activator inhibitor-1 (PAI-1), PAI-2, and protease nexin (PAI-3). 
PAI-1 and PAI-2 are the main inhibitors of the PAS, and they are most likely regulated 
differently since PAI-1 is a secreted protein and PAI-2 is mainly found in the cytoplasm . 
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When uPA binds to uPAR, it leads to the enhancement of plasmin production, the 
localization of proteolytic activity to the cell surface, and the activation of several signaling 
pathways  via  uPAR.  Since  uPAR lacks  transmembrane  and  cytosolic  domains,  it  must 
interact  with vitronectin  and integrins  to activate signaling pathways .  When PAI-1 is 
present, it binds to the uPA/uPAR/integrin complex, this complex is internalized, uPA and 
PAI-1  are  degraded,  and  uPAR  is  recycled  back  to  the  cell  surface.  Once  the 
uPA/uPAR/integrin complex is internalized, the cell is no longer attached to the ECM via the 
uPA/uPAR/integrin complex, and the cell is free to migrate. Therefore, while PAI-1 inhibits 
uPA protease  activity,  it  may be  important  for  cell  detachment.  Interestingly,  increased 
levels  of PAI-1 are indicative of a poor prognosis  for survival  in patients afflicted with 
several types of cancer, including breast, colon, and neuroblastoma . Moreover, uPA was 
recently shown to be up-regulated in meningioma cells in response to radiation, and that this 
lead to increased tumor invasion, migration, and angiogenesis in vivo . Moreover, down-
regulation of uPA and uPAR expression results in significantly decreased tumor invasion, 
migration, and angiogenesis in meningioma cells. Similarly, other studies have shown that 
neutralizing antibodies to uPA or uPAR , antisense oligonucleotides , and small molecules 
that target uPA or uPAR  may be important therapeutic targets to suppress tumor growth, 
invasion,  and metastasis.  Therefore,  since these components  of  the PAS seem to be so 
important for tumor invasion and metastasis,  we examined the regulation of the PAS in 
glioblastoma multiforme, which is the most invasive primary brain tumor (Chapter 2).  
1.6 Summary
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Chronic inflammation plays a pivotal role in disease progression, as it  provides a 
constant supply of pro-inflammatory cytokines and chemokines. In Chapters 2 and 3, we 
describe  that  IL-1-induced  mRNA and  protein  expression  of  the  plasminogen  activator 
system leads to increased invasion of glioblastoma U373 cells, and that IL-1 stimulation of 
primary  human  astrocytes  induces  the  mRNA  expression  of  two  T  cell  chemotactic 
chemokines  (IP-10 and RANTES),  respectively.  More  importantly,  since  IL-1  has  been 
shown to increase the expression of SphK1  and elevated levels of SphK1 indicate a poor 
prognosis  for survival  for glioblastoma patients ,  we investigated the role of S1P in the 
regulation  of  the  plasminogen  activator  system and  glioblastoma  invasion  (Chapter  2). 
Interestingly, as described in detail in Chapter 3, S1P also abolishes IL-1-induced mRNA 
expression of IP-10 and RANTES, which are both essential chemokines for the progression 
of MS. Therefore, S1P may be a focal therapeutic agent for the treatment of MS, as it may 
reduce the attraction of T cells to MS lesions.
CHAPTER 2 
SPHINGOSINE -1-PHOSPHATE AND INTERLEUKIN-1 
INDEPENDENTLY REGULATE THE PLASMINOGEN ACTIVATOR 
SYSTEM IN GLIOBLASTOMA; IMPLICATIONS FOR 
INVASIVENESS
2.1 ABSTRACT
Glioblastoma  multiforme  is  an  invasive  primary  brain  tumor,  which  evades  the 
current  standard treatments.  The invasion  of  glioblastoma cells  into healthy brain  tissue 
partly depends on the proteolytic and non-proteolytic activities of the plasminogen activator 
system proteins,  including the urokinase-type (uPA) plasminogen activator,  plasminogen 
activator inhibitor 1 (PAI-1), and a receptor for uPA (uPAR). Here we demonstrate that 
sphingosine-1-phosphate (S1P), and the inflammatory mediator IL-1, increase the mRNA 
and protein expression of PAI-1 and uPAR and enhance the invasion of U373 glioblastoma 
cells. Although IL-1 enhanced the mRNA expression of sphingosine kinase 1 (SphK1), the 
enzyme that produces S1P, downregulation of SphK1 had no effect  on the IL-1-induced 
uPAR or PAI-1 mRNA expression, suggesting that these actions of IL-1 are independent of 
S1P  production.  Indeed,  the  S1P-induced  mRNA  expression  of  uPAR  and  PAI-1  was 
blocked by the S1P2 receptor antagonist JTE013, and by the downregulation of S1P2 using 
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siRNA. Accordingly, the inhibition of MEK1/2 and Rho-kinase, two downstream signaling 
cascades activated by S1P2, blocked the activation of PAI-1 and uPAR mRNA expression by 
S1P. More importantly, the attachment of glioblastoma cells was inhibited by the addition of 
exogenous PAI-1 or siRNA to uPAR, while the invasion of glioblastoma cells induced by 
S1P or IL-1 correlated with their ability to enhance the expression of PAI-1 and uPAR. 
Collectively, these results indicate that S1P and IL-1 activate distinct pathways leading to the 
mRNA and protein expression of PAI-1 and uPAR, which are important for glioblastoma 
invasiveness.
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2.2 INTRODUCTION
Glioblastoma multiforme (GBM) is one of the most common and most malignant 
tumors of the central nervous system . Due to the invasive phenotype and diffuse penetration 
of  GBM  into  normal  regions  of  the  brain,  standard  treatments  such  as  surgery  and 
radiotherapy are  ineffective  .  It  is  for  these  reasons  that  patients  diagnosed with  GBM 
survive only an average of 10 to 12 months . The invasion of glioblastoma cells requires the 
degradation of the extracellular matrix (ECM), which depends on the activation/inhibition of 
proteinases and their inhibitors, respectively. These processes include two main proteolytic 
systems:  the  plasminogen  activator  system (PAS),  which  controls  the  activation  of  the 
proteinase plasmin from inactive plasminogen, and the matrix metalloproteinases and their 
inhibitors . 
In the brain, microglia produce inactive plasminogen, while astrocytes and glioma 
cells produce and secrete the components of the PAS. The PAS includes the plasminogen 
activators [urokinase-type (uPA), and the tissue-type (tPA)], their inhibitors [plasminogen 
activator  inhibitors  (PAI-1,  -2,  and  -3)  and  protease  nexin  1],  and  a  receptor  for  uPA 
[urokinase plasminogen activator receptor (uPAR)] . The binding of uPA to uPAR leads to 
the  localization  of  proteolytic  activity  to  the  cell  surface,  the  enhancement  of  plasmin 
production, and the activation of several signaling pathways via uPAR . Significantly, the 
expression of both uPA and uPAR has been correlated with the invasiveness and migration 
of several  cancer cell  lines .  Moreover, the knockdown of uPAR expression in gliomas, 
using RNAi, leads to a significant decrease in cell invasion in both Matrigel and spheroid 
invasion assays . Furthermore, transfecting glioblastoma cells with antisense uPA disrupted 
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actin cytoskeleton formation, reduced the amount of cell-bound uPA, and decreased cell 
migration . Surprisingly, high levels of PAI-1, which inhibit uPA, have been associated with 
highly invasive glioblastomas . Similarly, breast cancer patients with high levels of PAI-1 
have a poor prognosis for survival . Together, these observations support the recent findings 
that PAI-1 binds to the uPA/uPAR/integrin complex, which promotes the internalization of 
this complex, and subsequent cell detachment and metastasis . 
The expression of the components of the PAS is regulated by growth factors and 
cytokines, such as epidermal growth factor (EGF) and interleukin-1 (IL-1), respectively . 
Importantly, increased glioblastoma invasiveness and decreased patient survival correlates 
with PAI-1 and EGFR overexpression in tumors . Moreover, inhibition of EGFR tyrosine 
kinase suppresses the invasion of glioblastoma cells, and decreases uPAR protein levels . 
Recently, we have described a novel signaling pathway of EGF-mediated up-regulation of 
PAI-1 expression in glioblastoma cells, which requires the sequential activation of c-Src, 
PKCδ, and sphingosine kinase 1 (SphK1; ref in ). SphK1 produces the potent lipid mediator 
S1P by phosphorylating sphingosine and its expression correlates with the poor survival of 
patients with GBM . S1P has been shown to be mitogenic for several glioma cell lines, and 
to  enhance  their  motility  and  invasiveness  .  S1P  acts  through  five  G  protein-coupled 
receptors (S1P1-S1P5) to activate multiple signaling pathways; however, it  may also have 
intracellular actions through mechanisms that are not understood. 
IL-1 is a pro-inflammatory cytokine released by inflammatory cells in the brain due 
to inflammation caused by an injury or a growing tumor. In addition, glioblastomas have 
recently been shown to secrete substantial amounts of IL-1 , which incites the secretion of 
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other cytokines, such as IL-6 and IL-8, as well as promotes glioblastoma proliferation . IL-1 
has also been shown to stimulate the expression of several MMPs, tPA, uPA , yet nothing is 
known of its role in invasion of glioblastomas. Because IL-1 has been shown to activate 
SphK1 in other cell types , we investigated the effects of IL-1 and S1P on regulation of the 
components  of  the PAS system and invasion  in  glioblastoma cells.  We show that  S1P 
requires S1P2 to activate PAI-1 and uPAR mRNA expression, and although IL-1 markedly 
upregulates the mRNA expression of SphK1, it acts independently of S1P. Moreover, S1P 
and IL-1 cooperatively increase the invasion of U373 glioblastoma cells, as well as primary 
non-established GBM6 glioblastoma cells. Our data highlights the role of S1P and IL-1 in 
the regulation of PAI-1 and uPAR mRNA and protein expression, which are critical  for 
glioblastoma invasiveness.
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2.3 MATERIALS AND METHODS
2.3.1 Cell Culture. Human glioblastoma U373-MG cells were obtained from the American 
Type Culture Collection (Herndon, VA), while primary human non-established glioblastoma 
GBM6 and GBM12 cells  were  kindly  provided  by  Dr.  C.  David  James  (University  of 
California, San Francisco, CA).  The U373-TAM67 cells expressing the dominant-negative 
c-jun(TAM67) were described  previously .   Cells  were cultured in  Dulbecco's  modified 
Eagle's medium supplemented with 10% fetal calf serum, antibiotics, sodium pyruvate, and 
non-essential amino acids.
2.3.2 Cytokines and cell stimulation. Cells were stimulated with 10 ng/ml IL-1 (a gift from 
Immunex Corp., Seattle, WA) or the indicated amounts of S1P, as described previously . 
For the inhibitor studies,  cells  were pretreated with 1  µM SP600125, 10  µM SB202190 
(Sigma-Aldrich, St. Louis, MO), 1 µM JTE-013 (Tocris, Ellisville, MO), 0.3 µM VPC23019 
(Avanti Polar Lipids, Alabaster, Al), 5 µM Y27632, 5 µM Gö6983 (EMD Biosciences, Inc., 
San Diego, CA), 10 µM LY294002, or 1 µM U0126 1hr prior to stimulation (Cell Signaling 
Technology, Inc., Beverly, MA). 
2.3.3 Northern blot analysis.  Total RNA was prepared by phenol extraction exactly as 
described previously . Five-microgram samples of RNA were subjected to formaldehyde gel 
electrophoresis using standard procedures  and transferred onto Hybond-XL membranes (GE 
Healthcare  Bio-Sciences  Corp.)  according to  the manufacturer’s  instructions.  The  filters 
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were prehybridized at 65°C for 3 h in 0.5 M sodium phosphate buffer pH 7.2, 7% SDS, and 
1 mM EDTA. Then the filters were hybridized in the same solution with cDNA fragments of 
PAI-1, uPAR, and uPA labeled by random priming .  After the hybridization, nonspecifically 
bound radioactivity was removed by four washes in 40 mM phosphate buffer, 1% SDS, and 
1 mM EDTA at 65°C for 20 min each. 
2.3.4 Quantitative PCR (qPCR) uPAR, uPA, PAI-1, SphK1, and GAPDH mRNA levels 
were measured using TaqMan technology (Applied Biosystems, Foster City, CA) according 
to the supplier’s instructions.  Briefly, one µg of total RNA was reverse-transcribed using the 
high capacity cDNA archive kit.  Subsequently, the cDNA was diluted 10-fold (uPAR, uPA, 
PAI-1, and SphK1) or 100-fold (GAPDH).  For real-time PCR, pre-mixed primer-probe sets 
and TaqMan Universal PCR Master Mix were purchased from Applied Biosystems, and the 
cDNA was amplified using an ABI 7900HT cycler. 
2.3.5 Western blotting. Cells were lysed in 10 mM Tris pH 7.4, 150 mM sodium chloride, 1 
mM EDTA, 0.5% NP-40, 1% Triton X-100, 1 mM sodium orthovanadate, 0.2 mM PMSF, 
and protease inhibitor cocktail (Roche, Mannheim, Germany).  The protein amounts were 
quantified using the BCA assay. Subsequently, equal amounts of the proteins were resolved 
using SDS-PAGE, and electroblotted onto nitrocellulose membranes (Schleicher & Schuell, 
Keene, NH).  Polyclonal anti-ERK and anti-IκBα antisera were purchased from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA), while anti-phospho-ERK and anti-phospho-JNK were 
purchased  from  Cell  Signaling  Technology,  Inc.  (Beverly,  MA).   Antigen-antibody 
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complexes were visualized by enhanced chemiluminescence according to the manufacturer’s 
instructions (Pierce, Rockford, IL). 
2.3.6  Downregulation  with  siRNA.  Cells  were  equally  plated  at  approximately  70% 
confluency. S1P2, PAI-1, and uPAR expression was downregulated using SmartPool siRNA 
purchased from Dharmacon, Inc. (Lafayette, CO).  The siRNA (10µM) was transfected into 
the cells using Dharmafect 1 (Dharmacon) for 48hrs.
2.3.7 Attachment  assay.  Cells  were  scraped off  the dishes  in  PBS,  and dissociated  by 
pipetting.  The cells were pelleted by centrifugation, counted, and resuspended in FBS-free 
DMEM at 100,000 cells/200 µl.  Subsequently, the cells were incubated with 1 µM PAI-1 
(EMD Biosciences, Inc., San Diego, CA), or 1 µM BSA for 10 minutes at 37°C, and plated 
onto vitronectin-coated dishes.  The cells were allowed to adhere for 10 minutes, the medium 
containing the non-attached cells was removed, centrifuged, and the cells were counted in 
the  presence  of  trypan  blue  using  a  hemocytometer.  The  attachment  assay  that  was 
performed after transfection with PAI-1 or uPAR siRNA, was performed as described above 
with minor differences (50,000 cells/200  µl  and the cells  were allowed to adhere for 5 
minutes).
2.3.8 Invasion assay. The cells were stimulated with S1P (5 µM) and/or IL-1 (10 ng/ml) for 
18  hours.  The  invasion  of  the  cells  was  subsequently  measured  in  a  modified  Boyden 
28
chamber, using polycarbonate filters (25 by 80 mm, 12 μm pore size) coated with Matrigel 
(BD, Franklin Lakes, NJ; ref. ). Both IL-1 (10ng/ml) and S1P (100 nM) were added to both 
the upper and lower chamber, while the cells were added to the upper chamber at 5×104 
cells/well. After 7 h, non-migratory cells on the upper membrane surface were mechanically 
removed, and the cells that traversed and spread on the lower surface of the filter were fixed 
with methanol and stained with Diff-Quik (Fisher Scientific, Pittsburgh, PA). The invading 
cells were counted with an inverted microscope and a 10× objective . Each data point is the 
average number of cells in five random fields, and is the mean ± standard deviation (SD) of 
three individual wells. 
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2.4 RESULTS
2.4.1 S1P and IL-1 regulate the expression of the PAS in glioblastoma cells. 
Previous studies have suggested that S1P might regulate invasion of glioblastoma cells , 
yet the mechanism involved remained elusive. To this end, U373 glioblastoma cells were 
stimulated with both S1P and IL-1, since glioblastomas have recently been shown to secret 
substantial amounts of this neuroinflammatory cytokine , which also activates PAI-1 . Both 
S1P and IL-1 efficiently stimulated the mRNA (both transcripts generated by the alternative 
cleavage and polyadenylation; ref. ) and protein expression of PAI-1 and uPAR, while the 
mRNA expression of uPA was unaffected (Fig. 2.1A, B, and C). The effect of exogenous 
S1P on PAI-1 and uPAR mRNA expression was time- and dose-dependent, with activation 
observed as early as one hour after stimulation (Fig. 2.1D). Maximum activation of PAI-1 
and uPAR mRNA expression was observed at 5 µM S1P, but the effect was significant at a 
concentration as low as 10 nM. These results indicate that S1P affects the mRNA expression 
of the PAS components in glioblastoma cells, and its effects are further enhanced by IL-1. 
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Figure 2.1 S1P and IL-1 up-regulate the expression of uPAR and PAI-1 in glioblastoma 
cells.  U373 cells were treated with 10 ng/ml IL-1 or 5 µM S1P for 18 hours (A, B, and C), 
stimulated with 5  µM S1P for the indicated times (D, left panels), or stimulated with the 
indicated amounts of S1P or 10 ng/ml IL-1 for 18 hours (D, right panel). (C) Media were 
collected  and  cell  lysates  prepared  and  analyzed  by  Western  blotting  as  discussed  in 
Materials  and Methods.  RNA was isolated and subjected to analysis  either by Northern 
blotting or qPCR using TaqMan technology.  The lower panels in A and D show 28S RNA 
stained with ethidium bromide on the membrane as a loading control.  The qPCR data were 
normalized to GAPDH mRNA, and expressed as a ratio to mRNA levels in untreated cells.
31
32
2.4.2  S1P  activates  PAI-1  and  uPAR  mRNA  expression  via  multiple  signaling 
pathways.
The additive activation of both PAI-1 and uPAR mRNA expression by the combination 
of S1P and IL-1 (Fig. 2.1B), suggests that they may regulate the mRNA expression of these 
genes  by  distinct  pathways.   Both  S1P  and IL-1  have  been  shown to  activate  various 
signaling pathways in many cell types, leading to the reprogramming of gene expression 
profiles  .   In  glioblastoma  cells,  both  S1P  and  IL-1  induced  rapid  phosphorylation  of 
ERK1/2; however, the phosphorylation of JNK and the efficient degradation of IκBα, which 
is important for the activation of NF-κB, were restricted to IL-1 (Fig. 2.2A).  We employed 
several pharmacological inhibitors in order to identify the signaling pathway(s) regulating 
PAI-1 and uPAR mRNA expression in response to S1P in U373 cells.   The inhibition of 
PI3K  and  p38  (using  LY294002  and  SB202190,  respectively)  diminished  the  intrinsic 
mRNA expression of PAI-1,  but did not affect  the relative fold activation by S1P (Fig. 
2.2B).  In contrast, the inhibition of MEK1/2 and Rho-kinase (using U0126 and Y27632, 
respectively) blocked PAI-1 and uPAR upregulation by S1P (Fig. 2.2C).  In addition, the 
S1P-mediated uPAR activation was also inhibited by LY294002.  These results suggest that 
diverse  signaling  molecules,  including  MEK/ERK and  Rho-kinase,  regulate  the  mRNA 
expression of PAI-1 and uPAR in response to S1P. Since both MEK/ERK and Rho-kinase 
can activate AP-1 and both PAI-1 and uPAR expression are regulated by AP-1 in response to 
various stimuli , we tested whether this potent transcription factor may be implicated in the 
regulation of PAI-1 and uPAR mRNA expression in response to S1P and IL-1.  We utilized 
U373-TAM67 cells inducibly 
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Figure 2.2 Signaling pathways involved in S1P-stimulateed mRNA expression of PAI-1 
and uPAR.   (A) U373 cells  were stimulated with 10 ng/ml IL-1 or 5  µM S1P for the 
indicated times. The cell lysates were prepared, and analyzed by Western blotting with anti-
phospho-ERK, anti-phospho-JNK, anti-IκBα, anti-ERK. Blots were stripped and re-probed 
with anti-tubulin antibodies to insure equal loading and transfer. (B, C) U373 cells were 
pretreated with 1 µM U0126, 10 µM LY294002, 1 µM SP600125, 10 µM SB202190, 5 µM 
Go6983, or 5 µM Y27632 for 1 hour, and subsequently stimulated with 5 µM S1P for 18 
hours.  RNA was isolated,  and the mRNA expression of PAI-1 (B) and uPAR (C) was 
analyzed by qPCR.  The data were normalized to GAPDH mRNA, and expressed as a ratio 
to mRNA levels in untreated cells.  Asterisks indicate statistically significant inhibition.
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overexpressing dominant-negative c-jun(TAM67), which quenches the expression of AP-1-
dependent genes .  The intrinsic mRNA expression of PAI-1, its fold activation by both S1P 
and IL-1, and the marked increase by their combination were diminished, thus indicating that 
AP-1 is involved in the regulation of PAI-1 mRNA expression (Fig. 2.3).  In contrast, the 
mRNA expression of uPAR was not affected by c-jun(TAM67) overexpression (Fig. 2.3). 
These results argue that while genes encoding PAI-1 and uPAR are regulated by signals 
initiated by S1P and IL-1, the precise mechanisms of their regulation are distinct.
2.4.3 IL-1-activated PAI-1 and uPAR mRNA expression is SphK1-independent. 
Since IL-1 rapidly activates  and upregulates the expression of SphK1 in several other 
cell types , we examined the effect of IL-1 on SphK1 mRNA expression in glioblastoma 
cells.  The mRNA expression of SphK1 was significantly upregulated by IL-1 in U373 cells 
(Fig. 2.4A).  Thus, the IL-1-induced PAI-1 and uPAR mRNA expression could potentially 
be due to elevated levels of S1P produced in response to IL-1.  Because in many other cell 
types, S1P produced by agonist-stimulated SphK1 can activate cell surface S1P receptors in 
an  autocrine/paracrine  manner  ,  this  possibility  was  examined  by  downregulating  the 
expression of SphK1 with specific siRNA in U373 cells.  However,  IL-1-induced mRNA 
expression of PAI-1 and uPAR was not affected by the downregulation of SphK1 (Fig. 2.4B 
and C), thus indicating that this activation is SphK1-independent.  
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Figure 2.3 AP-1 is necessary for PAI-1, but not uPAR mRNA expression U373-TAM67 
cells were preincubated with 1 µg/ml of tetracycline for 24 hours, and then stimulated with 
10 ng/ml IL-1 or 5 µM S1P for 18 hours, RNA was isolated and analyzed as in (2.2 B, C).
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Figure 2.4 Upregulation of PAI-1 and uPAR mRNA by IL-1 is independent of SphK1. 
U373 cells were transfected with control or SphK1 siRNA for 48 hours, and then stimulated 
with or without 10 ng/ml IL-1 for 18 hours, as indicated.  RNA was isolated, and the mRNA 
expression of SphK1 (A), PAI-1 (B) and uPAR (C) was analyzed by qPCR.  The data were 
normalized to GAPDH mRNA, and expressed as a ratio to mRNA levels in untreated cells. 
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2.4.4 S1P activates PAI-1 and uPAR mRNA expression via the S1P2 receptor. 
Given that most of the effects of S1P are mediated by binding to specific cell surface 
receptors , of which S1P1-3 are expressed by U373 cells , it was of interest to identify the S1P 
receptor(s) mediating the activation of PAI-1 and uPAR mRNA expression. To this end, we 
utilized both pharmacological and molecular approaches.  First, antagonists VPC23019 and 
JTE-013 were used to block the S1P1 and S1P2 receptors, respectively.  Inhibition of S1P2 
abrogated the activation of PAI-1 and uPAR mRNA expression by S1P, while the inhibition 
of S1P1 was ineffective (Fig. 2.5A and B).  Moreover, neither the inhibition of S1P1 nor S1P2 
had any effect on the IL-1 activated mRNA expression of PAI-1 and uPAR (Fig. 2.5C and 
D), thus suggesting that the activation by IL-1 does not require these two receptors.  Second, 
the mRNA expression of S1P2 was down-regulated by more than 80% by S1P2  specific 
siRNA  (Fig.  2.6A).   In  agreement  with  the  pharmacological  inhibition  of  S1P2,  the 
downregulation  of  S1P2  expression abolished the activation of  PAI-1 and uPAR mRNA 
expression by S1P, without affecting the response to IL-1 (Fig. 2.6B and C).  These results 
indicate that S1P specifically activates PAI-1 and uPAR mRNA expression via the S1P2 
receptor.
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Figure 2.5 Inhibition of S1P2 blocks the induction of PAI-1 and uPAR mRNA by S1P. 
U373 cells  were  pretreated with 0.3  µM VPC23019 or 1  µM JTE-013 for 30 min., and 
subsequently stimulated with 5 µM S1P (A, B) or 10 ng/ml IL-1 (C, D) for 18 hours.  RNA 
was isolated, and the mRNA expression of PAI-1 (A, C) and uPAR (B, D) was analyzed by 
qPCR.  The data were normalized to GAPDH mRNA, and expressed as a ratio to mRNA 
levels in untreated cells.  
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Figure  2.6  Knock-down of  S1P2 expression  abrogates  S1P-induced  upregulation  of 
PAI-1 and uPAR mRNA.  U373 cells were transfected with control or S1P2 siRNA for 48 
hours.  Then the cells  were stimulated  without  or  with  10 ng/ml  IL-1 or  5  µM S1P as 
indicated, for 18 hours.  RNA was isolated, and the expression of S1P2 mRNA (A), PAI-1 
(B) and uPAR (C) mRNA was analyzed by qPCR.  The data were normalized to GAPDH 
mRNA, and expressed as  a  ratio  to  mRNA levels  in  untreated  cells.  Asterisks  indicate 
statistically significant inhibition.
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2.4.5  PAI-1  and  uPAR  are  critical  for  the  IL-1-  and  S1P-induced  invasion  of 
glioblastoma cells.
Subsequently, we examined the roles of PAI-1, uPAR, S1P, and IL-1 in the invasion of 
glioblastoma cells.  The invasion of U373 cells into Matrigel was significantly increased in 
response to both S1P and IL-1 (Fig. 2.7B).  More importantly, the S1P- and IL-1-induced 
invasion was abrogated in U373 cells when the expression of either PAI-1 or uPAR was 
downregulated (Fig. 2.7B).  Thus, both IL-1 and S1P increase the invasion of glioblastoma 
cells via PAI-1 and uPAR expression.  Since PAI-1 binds to, and induces the internalization 
of the PAI-1/uPA/uPAR/integrin complex,  which cause cell  detachment in  breast  cancer 
cells , we evaluated whether PAI-1 can interfere with the attachment of U373 cells. Indeed, 1 
µM PAI-1 inhibited the attachment of U373 cells to vitronectin-coated dishes (Fig. 2.8). 
These results suggest that PAI-1 may also regulate detachment of glioblastoma cells.
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Figure 2.7 PAI-1 and uPAR are indispensable for S1P- and IL-1-enhanced invasion of 
U373 cells.  (A,B) U373 cells were transfected with control, uPAR, or PAI-1 siRNA for 48 
hours, as indicated. (A) RNA was isolated, and the expression of uPAR and PAI-1 mRNA 
was analyzed by qPCR.  The data were normalized to GAPDH mRNA, and expressed as a 
ratio to mRNA levels  in untreated cells.  (B) Duplicate  cultures were stimulated with or 
without  10  ng/ml  IL-1  or  100  nM S1P for  12  hours,  and  allowed  to  migrate  through 
polycarbonate  filters  coated with Matrigel  for  7  hours.   The invasion  was measured as 
described in the Materials and Methods.  The results are means ± SD from three independent 
experiments.
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Figure 2.8 PAI-1 increases detachment of U373 cells. (A) U373 cells were incubated with 
1  µM PAI-1  or  1  µM BSA for  10  minutes,  plated  onto  vitronectin-coated  dishes,  and 
allowed to adhere for 20 minutes. Subsequently, the medium containing the non-attached 
cells  was removed, and the number of cells  present in the medium was counted using a 
hemocytometer. (B) U373 cells were transfected with control, uPAR, or PAI-1 siRNA for 48 
hours, as indicated. The cells were plated, allowed to adhere, removed, and counted exactly 
as performed in (A). The results are means ± SD from two independent experiments done in 
triplicate. 
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2.4.6 PAI-1 and uPAR mRNA expression is regulated by S1P and IL-1 in primary non-
established glioblastomas.
Glioblastoma cell lines, commonly used in  in vitro studies, are not invasive in  in vivo 
animal  models .   Therefore,  we examined the effects  of S1P and IL-1 on primary non-
established glioblastoma cells (GBM6 and GBM12), which were shown to produce invasive, 
diffuse tumors in scid mice .  mRNA expression of PAI-1 and uPAR was increased by S1P 
and IL-1 in GBM6 cells (Fig. 2.9A, B). However, whereas S1P increased PAI-1 in GBM12 
cells, IL-1 increased uPAR without affecting PAI-1 (Fig. 2.9A, B). In contrast to U373 cells, 
the mRNA expression of uPA was also upregulated by S1P and IL-1 in both of these non-
established GBM cells (Fig. 2.9C).  Moreover, the invasion of GBM6 cells into Matrigel was 
significantly increased in response to both S1P and IL-1 (Fig. 2.9D), while GBM 12 cells 
were not invasive (Fig. 2.9D), likely due to the extremely low levels of uPAR in these cells. 
Thus,  both  S1P and IL-1  play important  roles  in  regulating the expression  of  the PAS 
components, and the invasion of primary glioblastoma cells.
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Figure  2.9 IL-1 and S1P upregulate  the  mRNA expression  of  PAI-1 and uPAR in 
primary non-established GBMs and stimulate their invasion.  Primary non-established 
glioblastoma GBM6 and GBM12 cells were stimulated without or with 10 ng/ml IL-1 or 5 
µM S1P for 18 hours.  RNA was isolated, and the expression of PAI-1 (A), uPAR (B), and 
uPA (C)  was  analyzed  by  qPCR.   The  data  were  normalized  to  GAPDH mRNA,  and 
expressed as  a  ratio  to mRNA levels  in  untreated cells.   (D) GBM6 and GBM12 cells 
(50,000 cells/well)  were stimulated without or with 10 ng/ml IL-1 or 100 nM S1P, and 
allowed to migrate through polycarbonate filters coated with Matrigel for 7 hours.  The 
invasion was measured as described in the Materials and Methods.  The results are means ± 
SD from three independent experiments.
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2.5 DISCUSSION
The invasive phenotype of glioblastoma cells  is  the major obstacle in the successful 
treatment of patients diagnosed with GBM. While the precise mechanisms leading to the 
diffuse penetration of individual cells into normal regions of the brain are not understood, it 
is known that their invasion is regulated by growth factors, cytokines, and other signaling 
molecules, including bioactive lipids.  Among cytokines and growth factors, IL-1 and EGF 
have attracted most of the attention.  EGF is produced in the brain and readily crosses the 
blood-brain barrier , while its receptor (EGFR) is frequently amplified , overexpressed , or 
mutated  in glioblastomas.  Furthermore, the amplification and overexpression of EGFR is 
associated with high-grade progression , and patients expressing high levels of both EGFR 
and PAI-1 have a shorter prognosis for survival .  Similarly to EGF, IL-1 is readily found in 
the  brain,  and  can  be  produced  by  activated  microglia  and  astrocytes  surrounding  the 
necrotic  center  of  a  glioblastoma  tumor.   In  addition,  significant  amounts  of  IL-1  are 
produced by glioblastomas .  IL-1, as a potent neuroinflammatory cytokine, activates the 
expression of many genes in astrocytes and glioblastoma cells, including the genes encoding 
PAI-1 and SphK1.  Similarly, we have recently shown that EGF stimulates PAI-1 mRNA 
expression in glioblastomas via the activation of SphK1 , the enzyme that produces S1P. 
In this paper, we show that exogenous S1P activates PAI-1 and uPAR mRNA expression 
in both U373 cells (Fig. 2.1), as well as in primary invasive GBMs (Fig. 2.9).  In addition, 
S1P enhances uPA mRNA expression in primary GBMs.  However,  the precise cellular 
localizations of PAI-1, uPA, and uPAR are likely critical, since the attachment at the leading 
edge of a migrating cell, and the concurrent detachment at its trailing edge is imperative for 
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efficient migration and invasion.  More importantly, the enhanced expression of the PAS 
components may provide both the attachment, as well as the detachment depending on the 
ratio of PAI-1, uPA, and uPAR at specific locations on the cell’s membrane. Indeed, uPAR 
is mainly found at focal adhesion areas, rafts, and caveolae at the leading edge of migrating 
cells . uPAR is bound to catalytically active uPA, leading to the degradation of the ECM, 
and providing attachment via the uPA/uPAR/integrins complex.  In contrast, the enhanced 
expression of PAI-1 on the trailing edge of migrating cells may induce the internalization of 
the uPA/uPAR/integrin complex, and result in cell detachment. 
Our data indicate that the S1P-induced mRNA expression of PAI-1 and uPAR is 
mediated by S1P2,  as shown using pharmacological  inhibitors and specific  siRNA. S1P2 
inhibits  glioma  cell  migration  through  Rho  activation  and  the  Rho-kinase  signaling 
pathway  ,  which  is  probably  mediated  by  PTEN  activation  .  However,  a  recent  study 
demonstrates  that  S1P2 inhibits  glioma  cell  migration  through  Rho  signaling  pathways 
independent of PTEN . In agreement with our results, S1P2 was recently reported to enhance, 
rather than suppress, invasion most likely by increasing cell adhesion .  In addition, we show 
that S1P2 may also control the generation of plasmin, which is critical for the degradation of 
the  ECM,  by  regulating  the  expression  of  PAI-1  and  uPAR.   The  S1P2-mediated 
upregulation of PAI-1 and uPAR required functional Rho-kinase and MEK1.  The increased 
mRNA expression of uPAR induced by both S1P and IL-1 was AP-1-independent as shown 
in U373-TAM67 cells.  In contrast, the intrinsic mRNA expression of PAI-1, and the fold 
stimulation by both S1P and IL-1 was decreased in U373-TAM67 cells, suggesting that this 
gene is regulated at least in part by AP-1. 
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Moreover, we showed that IL-1 acts independently of S1P to stimulate PAI-1 and 
uPAR mRNA expression in U373 cells, as well as in primary GBMs. This may be relevant 
in vivo, since IL-1 is secreted by the majority of GBMs .  IL-1 can also regulate the levels of 
S1P in vivo, since it strongly upregulates the expression of SphK1 (Fig. 2.4A). However, the 
IL-1-mediated increase of PAI-1 and uPAR mRNA expression is independent of SphK1, and 
thus independent of S1P formation.  These data are further supported by the observation that 
the knockdown of S1P2 expression does not affect the IL-1-induced mRNA expression of 
PAI-1 and uPAR.  An additional role for IL-1 may lie in its ability to stimulate the mRNA 
expression of SphK1, thus maintaining a sustained pool of S1P, which is known to be critical 
for glioblastoma cell growth and survival .  More import, we demonstrate that the in vitro 
invasion of both U373 cells, and primary GBM6 cells was increased in response to both S1P 
and IL-1.  Furthermore, the down-regulation of both PAI-1 and uPAR expression abrogated 
S1P- and IL-1-induced invasion. Therefore, we propose that IL-1 and S1P independently 
stimulate the invasion of glioblastoma cells via upregulating PAI-1 and uPAR expression. 
These observations have important implications for development of future therapeutic agents 
to limit the invasion of GBM cells into surrounding healthy tissue, thus allowing for the 
effective removal of the tumor. 
CHAPTER 3 
NOVEL SPHINGOSINE -1-PHOSPHATE MEDIATED SUPPRESSION 
OF INTERLEUKIN-1-INDUCED CHEMOKINE EXPRESSION IN 
PRIMARY HUMAN ASTROCYTES
3.1 ABSTRACT
Multiple sclerosis (MS), an inflammatory disease of the central nervous system, is 
hallmarked by chronic inflammation, demyelination, and brain atrophy. The pathology of 
this disease is mostly due to autoreactive T cells that invade the blood-brain barrier,  and 
become activated. In the brain, T cells are attracted to sites of inflammation by chemokines 
released by activated microglia and astrocytes. Interestingly, two potent T cell chemokines, 
interferon gamma inducible protein-10 (IP-10) and  regulated on activation normal T-cell-
expressed and secreted (RANTES), are up-regulated in MS lesions. Here we show for the 
first time that in primary human astrocytes, sphingosine -1-phosphate (S1P), the bio-active 
sphingolipid, can significantly repress IP-10 and RANTES mRNA expression induced by the 
major proinflammatory cytokine of the brain, interleukin-1 (IL-1). IL-1 activates IP-10 and 
RANTES mRNA expression by inducing interferon beta (IFNβ) mRNA expression,  and 
56
57
subsequently the activation/phosphorylation of STAT1 and STAT2, which are known to be 
important for IP-10 and RANTES promoter activity. More importantly, S1P inhibits IFNβ 
production, STAT1 and STAT2 activation, and IP-10 and RANTES mRNA expression, via a 
novel mechanism involving the hyper-phosphorylation of TAK1, which is a key component 
of the IL-1 signaling pathway. In addition, the S1P repression of IP-10 and RANTES is 
receptor-mediated, and depends on the Gi protein, as it is pertussis toxin sensitive and can be 
blocked by S1PR antagonists. These significant results could have implications for future 
MS therapies utilizing S1P as a natural compound to reduce self-destructive inflammation.
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3.2 INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS that affects 
over one million people worldwide . It affects women twice as often as men, and it typically 
occurs in young adults. The disease is characterized by demyelination, axonal loss, and brain 
atrophy . Demyelination produces plaques, which are areas of white matter where in the 
inflammatory response has removed the myelin from neurons, and cells such as actrocytes 
and  microglia  have  caused  scarring.  Hence,  the  major  pathology  of  MS is  due  to  the 
inflammatory response, specifically autoreactive T cells. In fact, in the animal model of MS, 
experimental autoimmune encephalomyelitis (EAE), the basic requirement for stimulating 
CNS inflammation and MS is activation of myelin reactive T cells in the peripheral immune 
system . 
In the brain, T cells and other immune cells are directed to sites of inflammation by 
chemotactic cytokines, called chemokines, which are released by activated microglia and 
astrocytes. Interestingly, two T cell chemotatic chemokines, interferon γ inducible protein-10 
(IP-10) and regulated on activation normal T cell expressed and secreted (RANTES), have 
been found to  be up-regulated  in  lesions  of  MS patients  (85,86,91,92).  Moreover,  anti-
CXCL10 (IP-10) mAbs reduce disease occurrence, severity, and invasion of mononuclear 
cells  .  In  addition,  a  RANTES  variant  (termed  44AANA47-RANTES),  which  lacks 
glycosaminoglycan  (GAG)  binding  properties  ,  impedes  disease  onset  and  diminishes 
disease score in the EAE model .  Thus, treatments that target these chemokines may be 
efficacious as future therapies for MS patients. 
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Interestingly,  increased levels  of interleukin-1 (IL-1),  the major pro-inflammatory 
cytokine in the brain, have also been found in MS lesions [66, 68]. IL-1 is released from 
activated microglia and astrocytes during inflammation, and has been shown to increase the 
expression of a variety of cytokines and chemokines, including IL-8, IL-6, TNFα, MCP-1, 
MIP-1α, MIP-1β, IP-10, and RANTES . More interestingly, in primary human astrocytes, 
IL-1 also increases the expression of sphingosine kinase 1 (SphK1), which is the enzyme 
responsible for producing the bioactive sphingolipid, sphingosine-1-phosphate (S1P) . 
S1P has been implicated in cell proliferation, survival, angiogenesis, migration, and 
differentiation in an assortment of cell types . S1P can act both intracellularly as a second 
messenger,  and extracellularly,  in  an  autocrine/paracrine  manner,  by  binding to  its  five 
transmembrane G-protein coupled receptors (S1P1-5) ;  however,  only S1P1-3  and S1P5 are 
expressed in the brain . The individual S1P receptors can couple to a distinct group of G 
proteins,  with  varying  affinities  for  different  affecter  molecules,  which  can  lead  to  the 
activation of mitogen-actvated protein kinase (MAPK/ERK), phospholipase C (PLC), PI3K, 
Rac, Rho, and JNK (Rev. in ). Notably, all of the S1P receptors are capable of coupling to 
the Gi protein; while only S1P2 and S1P3 can couple to Gq, and only S1P2, S1P3, and S1P5 
couple to G12/13 . Furthermore, S1P receptors are significantly increased in the borders of MS 
lesions . 
Here we demonstrate for the first time, that IL-1-induced IP-10 and RANTES mRNA 
expression is abolished by S1P in primary human astrocytes. The S1P-directed suppression 
of IL-1-induced IP-10 and RANTES mRNA expression is Gi mediated, and involves a key 
component of IL-1 signaling, TAK1. Furthermore, S1P suppression of IP-10 and RANTES 
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mRNA  expression  also  occurs  in  other  cell  types,  including  MEFs  (mouse  embryonic 
fibroblasts)  and  HeLa  cells.  Moreover,  S1P  also  suppresses  TNFα-induced  mRNA 
expression of IP-10 and RANTES. Thus, S1P is capable of suppressing cytokine induced 
mRNA expression  of  T  cell  chemokines  in  primary  human  astrocytes,  and  therefore,  a 
natural sphingolipid (S1P) may be an important therapeutic agent for inhibiting the T cell 
response in MS patients in the future. 
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3.3 MATERIALS AND METHODS
3.3.1 Cell culture. Human glioblastoma U373-MG and HeLa epitheloid cervix carcinoma 
cells  were obtained from the American Type Culture Collection (Herndon, VA).  Mouse 
embryonic fibroblasts were purchased from Millipore Corporation, Phillipsburg, NJ, while 
TAK1 KO MEFs were kindly provided by Dr. Xiaoxia Li (Cleveland Clinic Foundation, 
Cleveland, OH). Cells were cultured in Dulbecco's modified Eagle's medium supplemented 
with 10% fetal calf serum, antibiotics, sodium pyruvate, and non-essential amino acids. Prior 
to  stimulation,  cells  were  cultured  overnight  in  Dulbecco’s  modified  Eagle’s  medium 
supplemented  with  1% fetal  calf  serum,  antibiotics,  sodium pyruvate,  and  non-essential 
amino acids.
3.3.2.  Primary  human  astrocytes  culture.  Human  cortical  astrocyte  cultures  were 
established using dissociated human cerebral tissue, as previously described . Cortical tissue 
was  provided  by Advanced Bioscience  Resources  (Alameda,  CA),  and the protocol  for 
obtaining  postmortem fetal  neural  tissue  complied  with  the  federal  guidelines  for  fetal 
research and with the Uniformed Anatomical Gift Act. Cells were cultured in Dulbecco’s 
modified  Eagle’s  medium  supplemented  with  10%  fetal  calf  serum,  penicillin  and 
streptomycin, sodium pyruvate, and non-essential amino acids. Prior to stimulation, cells 
were cultured overnight in Dulbecco’s modified Eagle’s medium supplemented with 1% 
fetal calf serum, antibiotics, sodium pyruvate, and non-essential amino acids.
62
3.3.3 Cytokines and cell stimulation.  Cells were stimulated with 10 ng/ml or the indicated 
amounts  of  IL-1α (a  gift  from Immunex  Corp.,  Seattle,  WA),  10  ng/ml  IL-1β (R&D, 
Systems, Inc., Minneapolis, MN), 10 ng/ml of human cell expressed IL-1β (Humanzyme, 
Chicago,  IL),  100  pg/ml  LPS  (Sigma-Aldrich,  St.  Louis,  MO),  5  ng/ml  TNFα (R&D, 
Systems, Inc., Minneapolis, MN), 1000 u/ml IFNα and 1000 u/ml IFNβ were a kind gift of 
Dr. Darren P. Baker (Biogen Indec Inc), 1000 u/ml IFNγ (R&D, Systems, Inc., Minneapolis, 
MN), or the indicated amounts of S1P, as described previously .  For the inhibitor studies, 
cells were pretreated with 1  µM JTE-013 (Tocris, Ellisville, MO), or 10  µM VPC23019 
(Avanti Polar Lipids, Alabaster, AL) 30 min prior to stimulation. Cells were also pretreated 
with  5  µM  Bay11-7082  inhibitor  (Sigma-Aldrich,  St.  Louis,  MO),  15  µM  MG132 
Proteasome Inhibitor (Santa Cruz, CA), and 20  µg/ml cycloheximide (Sigma-Aldrich, St. 
Louis,  MO) for 1 hr prior to stimulation; whereas, 600 nM TAK1 inhibitor (AnalytiCon 
Discovery, Potsdam, Germany) and 200 ng/ml pertussis toxin (Sigma-Aldrich, St.  Louis, 
MO) were used for 3 hrs and 24 hrs prior to stimulation, respectively. 
3.3.4 RNA preparation and quantitative PCR (qPCR).  Cultured cells  were lysed by 
Trizol (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions to prepare 
total  RNA. IL-8,  MIP-1β,  IP-10,  RANTES, IFNβ,  IL-6,  mouse IP-10,  mouse RANTES, 
mouse  GAPDH,  and  GAPDH mRNA levels  were  measured  using  TaqMan  technology 
(Applied Biosystems, Foster City, CA) according to the supplier’s instructions.  Briefly, one 
µg  of  total  RNA  was  reverse-transcribed  using  the  high  capacity  cDNA  archive  kit. 
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Subsequently, the cDNA was diluted 10-fold (IL-8, MIP-1β, IP-10, RANTES, IFNβ, IL-6, 
mouse IP-10, and mouse RANTES) or 100-fold (mouse GAPDH and GAPDH).  For real-
time  PCR,  pre-mixed  primer-probe  sets  and  TaqMan Universal  PCR Master  Mix  were 
purchased from Applied Biosystems, and the cDNA was amplified using an ABI 7900HT 
cycler. 
3.3.5 Reporter constructs and transient transfections.  Cells were transiently transfected 
in 12 well clusters by FuGENE6 transfection reagent (Roche, Indianapolis, IN) according to 
the supplier’s instructions. For the Luciferase reporter assays, four hundred ng of the reporter 
Luciferase plasmids NFκB-Luc (Stratagene, USA), pGL-IP-10Luc, pTGL-IP10Luc, pISRE-
IP10Luc, pκB2-MutLuc (all of which were donated by Dr. Richard Ransohoff (Cleveland 
Clinic Foundation, Cleveland, OH), as well as 100 ng of the expression plasmid encoding β-
galactosidase were used per well in a 12 well cluster. 
3.3.6 Western blotting.  Cells were lysed in 10 mM Tris pH 7.4, 150 mM sodium chloride, 
1 mM EDTA, 0.5% NP-40, 1% Triton X-100, 1 mM sodium orthovanadate, 0.2 mM PMSF, 
and protease inhibitor cocktail (Roche, Mannheim, Germany).  The protein amounts were 
quantified using the BCA assay. Subsequently, equal amounts of the proteins were resolved 
using SDS-PAGE, and electroblotted onto nitrocellulose membranes (Schleicher & Schuell, 
Keene, NH).  Polyclonal anti-IkBα, anti-phospho-MEKK1, anti-β-tubulin, anti-phospho-c-
Jun, and anti-IRAK1 antisera were purchased from Santa Cruz Biotechnology, Inc. (Santa 
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Cruz,  CA).  The  anti-TAK1,  anti-phospho-TAK1  (Thr184/187),  anti-phospho-TAK1 
(Ser412),  anti-p38,  anti-phospho-p38,  anti-phospho-IKKα/β,  anti-phospho-MKK4,  anti-
phospho-MKK3/6,  anti-phopho-STAT1,  anti-phospho-STAT2,  anti-phospho-ATF2,  anti-
phospho-p65, and anti-phospho-JNK were purchased from Cell Signaling Technology, Inc. 
(Beverly,  MA).   Antigen-antibody  complexes  were  visualized  by  enhanced 
chemiluminescence according to the manufacturer’s instructions (Pierce, Rockford, IL). 
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3.4 RESULTS
3.4.1 S1P represses IL-1-induced mRNA expression of IP-10 and RANTES in human 
primary astrocytes.
Previous studies have shown that IL-1 induces the expression of various chemokines 
(IL-8, MIP-1β, IL-6, IP-10, and RANTES) [94,95] in astrocytes, and it also stimulates the 
expression  and activation  of sphingosine kinase-1 (SphK1), and thus the generation of S1P. 
Conversely, nothing is known about the regulation of these chemokines by S1P in astrocytes. 
To  this  end,  primary  human  astrocytes  were  stimulated  with  both  S1P  and  IL-1.  IL-1 
significantly enhanced the mRNA expression of IP-10 and RANTES in these cells, while 
S1P greatly inhibited the stimulation by IL-1 (Figure 3.1 A and B). It is also important to 
note that the kinetics of IP-10 and RANTES stimulation by IL-1 was very different, as IP-10 
mRNA expression  peaked  at  8  hours,  while  RANTES mRNA expression  continued  to 
increase  up  to  18  hours.  In  order  to  determine  the  specificity  of  the  S1P  chemokine 
suppression, we also examined the mRNA expression levels of IL-8, IL-6, and MIP-1β after 
S1P and IL-1 stimulation. In contrast to IP-10 and RANTES expression, S1P synergized 
with IL-1 to increase the mRNA expression of IL-8, IL-6, and MIP-1β (Figure 3.2 A, B, and 
C).  These  results  indicate  that  S1P  specifically  represses  IP-10  and  RANTES  mRNA 
expression.
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Figure 3.1 S1P inhibits IL-1-induced mRNA expression of IP-10 and RANTES. Primary 
human astrocytes were stimulated with 10 ng/ml IL-1, or 5 µM S1P for the indicated times 
(A, B). RNA was isolated, and analyzed by qPCR using Taqman technology. qPCR data 
were normalized to GAPDH mRNA, and expressed as a ratio to mRNA levels in untreated 
cells. The experiment was performed two times, and one is shown.
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Figure  3.2 S1P and IL-1 up-regulate  the  mRNA expression  of  the  IL-8,  IL-6,  and 
MIP-1β genes. Astrocytes were treated with 10 ng/ml IL-1 and 5 µM S1P for the indicated 
times. RNA was isolated, and the expression of IL-6 (A), IL-8 (B), and MIP-1β (C) were 
analyzed  by  qPCR  using  TaqMan  technology.  Data  were  normalized  to  GAPDH,  and 
expressed as a ratio to mRNA levels in untreated cells. The experiment was performed two 
times, and a representative is shown. 
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3.4.2  S1P  suppresses  IL-1-  and  TNFα-  induced  mRNA  expression  of  IP-10  and 
RANTES in several cell types.
Since  S1P  suppressed  IL-1-induced  IP-10  and  RANTES  mRNA  expression  in 
astrocytes,  we  analyzed  whether  this  inhibition  was  astrocyte-  and  IL-1-specific. 
Interestingly, S1P also quenched IL-1 stimulated IP-10 and RANTES mRNA expression in 
U373 glioblastoma, HeLa, and mouse embryonic fibroblasts (MEFs) (Figure 3.3 A, B, and 
C). The fold activation of IP-10 and RANTES mRNA expression by IL-1 was significantly 
lower, which is likely due to the higher basal mRNA expression of IP-10 and RANTES in 
these cells. As IL-1α and IL-1β have similar signaling (ref. in ), we stimulated astrocytes 
with IL-1β and S1P to confirm that S1P can also inhibit IL-1β signaling. Indeed, IL-1α and 
IL-1β similarly activated IP-10 and RANTES mRNA expression, and S1P suppressed IL-1β 
as efficiently as IL-1α (Figure 3.4 A and B). Furthermore, we investigated whether S1P can 
also  inhibit  TNFα-induced chemokine  mRNA expression.  In  fact,  S1P quenched TNFα 
induced  mRNA  expression  of  both  IP-10  and  RANTES  (Figure  3.5  A  and  B),  thus 
suggesting a common mechanism of inhibition. It is important to note, that recombinant 
cytokines may contain trace amounts of LPS, which also activates chemokine expression in 
various cell types. Although astrocytes do not respond to low doses of LPS, microglia, which 
may be a contaminant of an astrocyte culture, are known to be activated by LPS . In order to 
verify that the observed chemokine mRNA expression is due to IL-1 stimulation and not 
LPS, we 
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Figure 3.3 S1P represses IL-1-induced chemokine gene expression in a variety of cell 
types. U373 glioblastoma cells, HeLa cells, and mouse embryonic fibroblasts (MEFs) were 
stimulated with 10 ng/ml IL-1 and 5 µM S1P for 8 hours (A, B, and C). RNA was isolated, 
and  analyzed  by  qPCR using  TaqMan technology.  The  qPCR data  were  normalized  to 
GAPDH  mRNA,  and  expressed  as  a  ratio  to  mRNA  levels  in  untreated  cells.  The 
experiments were performed in triplicate, and a representative is shown. 
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Figure  3.4  IL-1α and IL-1β induce  IP-10 and RANTES gene  expression  similarly. 
Astrocytes were treated with 10 ng/ml IL-1α and IL-1β, as well as 5 µM S1P (A and B). 
RNA was isolated and the expression of IP-10 (A) and RANTES (B) was analyzed by qPCR. 
Data were normalized to GAPDH, and expressed as a ratio to mRNA levels in untreated 
cells. The experiment was performed in triplicate, and one is shown. 
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Figure 3.5 S1P effectively represses TNFα-induced mRNA expression of IP-10 and 
RANTES. Primary human astrocytes were stimulated with 10 ng/ml IL-1β, 10 ng/ml IL-1β 
derived from human cells, 5 ng/ml TNFα, and 5 µM S1P for 8 hours (A and B). RNA was 
analyzed, and subsequently analyzed by qPCR. The data were normalized to GAPDH, and 
expressed as a ratio to untreated cells. The experiment was performed in triplicate, and a 
representative is shown. 
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stimulated astrocytes with IL-1β isolated from human cells, recombinant IL-1α heated with 
trypsin, and compared their stimulation of IP-10 and RANTES mRNA expression to the 
chemokine activation in  response to  100 pg of  LPS (10 fold higher  than the suspected 
amount of LPS in the recombinant cytokines). Importantly, IL-1β expressed in human cells 
stimulated  IP-10 and RANTES mRNA expression,  although to  a  lesser  extent  than the 
recombinant  IL-1β,  and S1P still  inhibited this  stimulation (Figure 3.6 A and B).  More 
importantly,  incubation  of  recombinant  IL-1α with  trypsin,  significantly  reduced  the 
activation of IP-10 and RANTES mRNA expression, and 100 pg/ml LPS did not stimulate 
IP-10 and RANTES mRNA expression at all (Figure 3.6 A and B). These results indicate a 
common component  of  IL-1 and TNFα signaling targeted by S1P to  repress IP-10 and 
RANTES mRNA expression. This S1P-induced mechanism of inhibition also functions in 
several cell types. 
3.4.3 Inhibition of IL-1-induced IP-10 and RANTES mRNA expression is specific to 
S1P.
In order to determine that the inhibition of IL-1-induced IP-10 and RANTES gene 
expression is specific to S1P, we treated cells with sphingosine and LPA, since LPA was 
shown to regulate chemokine expression .  In fact,  the inhibition of IP-10 and RANTES 
mRNA expression was exclusive to S1P, as Sph and LPA were relatively ineffective (Figure 
3.7 A and B). Furthermore, the effects of both IL-1 and S1P on IP-10 and RANTES mRNA 
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expression were dose-dependent. IL-1 activated IP-10 and RANTES mRNA expression at a 
concentration as low as .1 ng (Figure 3.8 A and B). More 
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Figure 3.6 LPS does not stimulate IP-10 and RANTES mRNA expression in astrocytes. 
Primary human astrocytes were stimulated with 10 ng/ml IL-1α, 10 ng/ml trypsinized IL-1α, 
100 pg/ml LPS, and 5 µM S1P for 8 hours. RNA was isolated, and the expression of IP-10 
(A) and RANTES (B) were analyzed by qPCR. The data were normalized to GAPDH, and 
expressed as  a  ratio  to  untreated cells.  A representative of  two separate  experiments  is 
shown. 
80
81
Figure 3.7 Repression of IL-1-induced IP-10 and RANTES mRNA expression is specific 
to S1P. Astrocytes were stimulated with 10 ng/ml IL-1β, 1 µM S1P, 1 µM LPA, and 1 µM 
Sph for 8 hours (A and B). RNA was isolated, and subjected to qPCR analysis. Data were 
normalized to GAPDH, and expressed as a ratio to untreated cells.  The experiment was 
performed two separate times, and a representative is shown.
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Figure 3.8 IL-1 stimulates IP-10 and RANTES mRNA expression at a dose as low as 0.1 
ng/ml. Astrocytes were treated with the indicated amounts of IL-1α and 5  µM S1P for 8 
hours. Subsequently, RNA was isolated, and the expression of IP-10 (A) and RANTES (B) 
was analyzed by qPCR. Data were normalized  to GAPDH, and expressed as a  ratio  to 
untreated cells. The experiment was performed in triplicate, and a representative is shown. 
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Figure 3.9 S1P represses IP-10 and RANTES mRNA expression at a concentration as 
low  as  10  nM. Primary  human  astrocytes  were  treated  with  10  ng/ml  IL-1α,  and  the 
indicated amounts of S1P for 8 hours (A and B). RNA was isolated, and analyzed by qPCR. 
Data  were  normalized  to  GAPDH,  and  expressed  as  a  ratio  to  untreated  cells.  The 
experiment was performed twice, and a representative is shown. 
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importantly, S1P suppressed IP-10 and RANTES mRNA expression at a concentration as 
low as 10 nM (Figure 3.9 A and B). These results suggest that S1P likely inhibits IP-10 and 
RANTES via a receptor mediated-mechanism.
3.4.4  S1P  repression  of  IL-1-stimulated  IP-10  and  RANTES  mRNA  expression  is 
receptor and Gi mediated.
Most of the known effects of S1P are mediated via the G protein-coupled receptors . 
Thus we first established that S1P1-3 are expressed by astrocytes, while S1P4 was not present 
in these cells and S1P5 was minimally expressed (Figure 3.10), which is in agreement with 
previously published results . Subsequently, it was important to identify which of the S1P 
receptors  mediates  the  suppression  of  IL-1-stimulated  IP-10  and  RANTES  mRNA 
expression.  Consequently,  we utilized pharmacological  inhibitors  (pertussis  toxin (PTX), 
JTE-013, and VPC23019), since specific siRNA to each receptor could not be used due to 
the  subsequent  interferon  response,  which  stimulates  both  IP-10  and  RANTES  mRNA 
expression  .  First,  we utilized  pertussis  toxin  (PTX),  which  inhibits  the Gi protein  that 
couples to all S1P receptors. PTX significantly reduced the inhibition of IP-10 by S1P, while 
it almost completely reversed the inhibition of IL-induced RANTES mRNA expression by 
S1P (Figure 3.11 A and B). Interestingly, the VPC23019 inhibitor, which at a concentration 
of 10 µM inhibits both S1P1 and S1P3, was ineffective at blocking S1P suppression of IP-10 
and RANTES mRNA expression (Figure 3.12 A and B). Conversely, the JTE-013 inhibitor, 
which  blocks  S1P2 signaling,  was  successful  in  blocking  S1P  inhibition  of  the  two 
chemokines (Figure 3.12 A and B). 
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Figure 3.10 S1P receptor mRNA expression in primary human astrocytes. RNA from 
untreated primary human astrocytes was analyzed by qPCR using TaqMan technology. The 
mRNA expression of S1P1, S1P2, and S1P3 were normalized to GAPDH, and expressed as a 
ratio  relative  to  S1P1 expression.  Primer  efficiencies  were  calculated,  and  S1P1 primer 
efficiency was similar to that of S1P2 and S1P3. S1P4 was not expressed, and expression 
levels of S1P5 are approximately 10,000 times less than those of S1P1, S1P2, and S1P3. 
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Figure 3.11 PTX blocks the S1P mediated suppression of IP-10 and RANTES mRNA 
expression.  Astrocytes  were  treated  with  200  ng/ml  pertussis  toxin  (PTX)  overnight. 
Subsequently, astrocytes were stimulated with 10 ng/ml of IL-1 or 1 µM S1P for 8 hours. 
RNA was isolated,  and the expression of IP-10 (A) and RANTES (B) was analyzed by 
qPCR. The data were normalized to GAPDH mRNA, and expressed as a ratio to mRNA 
levels in untreated cells. The experiment was performed in duplicate, and a representative is 
shown.
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Figure  3.12  S1P2 mediates  S1P-induced  repression  of  IP-10  and  RANTES  mRNA 
expression. Astrocytes  were  treated  with  1  µM  JTE-013  (inhibits  S1P2)  and  10  µM 
VPC23019 (inhibits S1P1 and S1P3) for 30 minutes prior to stimulation with 10 ng/ml IL-1 
and 100 nM S1P for 8 hours. RNA was isolated, and analyzed by qPCR. The expression of 
IP-10 (A) and RANTES (B) was normalized to GAPDH, and expressed as a ratio to mRNA 
in untreated cells. A representative of five separate experiments is shown. 
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Together, these results indicate that S1P suppression is mediated by S1P2, and is pertussis 
toxin sensitive.
3.4.5 Inhibition of IP-10 and RANTES mRNA expression by S1P is not mediated via 
NF-κB.
Since the NF-κB binding sites within both the IP-10 and RANTES promoters play an 
important role in their activation , and IL-1 stimulates NF-κB, we investigated whether S1P 
could inhibit the activation of NF-κB by IL-1. Accordingly, we analyzed the degradation of 
the inhibitor of NF-κB (IκBα), and the phosphorylation of IKKα/β, which is the kinase that 
phosphorylates IκBα.  S1P weakly induced both the phosphorylation of IKKα/β,  and the 
degradation of IκBα. In addition, IL-1 substantially stimulated IKKα/β phosphorylation and 
IκBα degradation (Figure 3.13 A and B). More importantly, S1P, in conjunction with IL-1, 
neither inhibited the IL-1-induced phosphorylation of IKKα/β, nor the degradation of IκBα. 
Moreover, an NF-κB reporter, containing three NF-κB sites fused to the tk promoter was 
stimulated  by  both  S1P  and  IL-1  alone,  and  their  effects  were  additive  when  used 
concomitantly (Figure 3.14). These data clearly demonstrate that S1P can not inhibit NF-κB 
activation. We further verified these findings using the pharmacological inhibitor of IKKα/β, 
Bay11-7082.  This  inhibitor  significantly  reduced the IL-1-induced mRNA expression of 
IP-10 and RANTES; however, it did not block the inhibitory properties of S1P (Figure 3.15 
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A and  B).  In  accordance  with  these  results,  the  proteasome inhibitor,  MG-132,  totally 
abolished IL-1 
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Figure 3.13 S1P and IL-1 stimulate components  necessary for activation of NF-κB. 
Astrocytes were stimulated with 5 µM S1P and 10 ng/ml IL-1 for the indicated times. The 
cell  lysates  were  prepared,  and  analyzed  by  Western  blotting  with  anti-IκBα and  anti-
phospho-IKKα/β (A, B). The blots were stripped and re-probed with anti-tubulin antibodies 
to insure equal loading and transfer (A, B). 
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Figure 3.14 NF-κB reporter construct is activated by S1P and IL-1.  Astrocytes were 
transiently transfected with the NF-κB-Luc reporter.  Subsequently,  cells  were stimulated 
with 10 ng/ml IL-1 and 5 µM S1P for 8 hours. Cell lysates were collected, and luciferase 
activity  was  measured.  The  luciferase  activity  was  normalized  to  β-galactosidase.  A 
representative of three separate experiments is shown. 
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Figure 3.15 Bay11-7082 significantly reduces IL-1-induced IP-10 and RANTES mRNA 
expression. Astrocytes were treated with 5 µM of the Bay11-7082 inhibitor for 1 hour prior 
to stimulation with 10 ng/ml IL-1 and 5 µM S1P for 8 hours. RNA was isolated, and qPCR 
analysis  was  performed.  The  mRNA  expression  of  IP-10  (A)  and  RANTES  (B)  was 
normalized to the mRNA expression of GAPDH, and expressed as a ratio to mRNA in 
untreated cells.  The experiment was performed twice, yielding similar results, and one is 
shown. 
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Figure  3.16  Proteasome  inhibition  by  MG-132  abolishes  IL-1-induced  mRNA 
expression of IP-10 and RANTES. Astrocytes were treated with 15 µM MG-132 inhibitor 
for 1 hour prior to stimulation with 10 ng/ml IL-1 and 5  µM S1P for 8 hours. RNA was 
isolated, and the mRNA expression of IP-10 (A) and RANTES (B) was analyzed by qPCR. 
The data were normalized to GAPDH mRNA, and expressed as a ratio to mRNA levels in 
untreated cells. A representative result of two separate experiments is shown. 
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stimulation of IP-10 and RANTES mRNA expression (Figure 3.16 A and B). These results 
indicate that while NF-κB expression is absolutely necessary for IP-10 and RANTES mRNA 
expression in response to IL-1, NF-κB is not responsible for the inhibitory action of S1P.
3.4.6 S1P and IL-1 activate multiple signaling pathways.
Given that NF-κB activation by IL-1 is not suppressed by S1P, we investigated other 
pathways known to be activated by IL-1. Primary human astrocytes were stimulated with 
S1P and IL-1 for a series of short time points, and the protein expression of total TAK1, 
phophorylated c-Jun, phosphorylated JNK, phosphorylated p65, and phosphorylated ATF2 
were analyzed (Figure 3.17). We discovered that S1P did not have an adverse affect on any 
of the IL-1-induced signaling pathways analyzed. However, it was further confirmed that 
NF-κB is enhanced by S1P, and that S1P does not inhibit the IL-1-induced phosphorlyation 
of NF-κB.  
3.4.7 S1P blocks the IL-1-induced mRNA expression of IFNβ, and the phosphorylation 
of STAT1 and STAT2.
In addition to NF-κB binding sites, both the IP-10 and RANTES promoters possess 
ISRE binding sites, which bind the STAT1/STAT2/IRF9 heterotrimer . In addition, the IP-10 
promoter contains a GAS element that binds STAT1/STAT1 homodimers . Since STAT1 
and STAT2 are important for the regulation of both IP- 
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Figure  3.17  S1P  and  IL-1  stimulate  multiple  signaling  pathways.  Astrocytes  were 
stimulated with 10 ng/ml IL-1 and 5  µM S1P for the indicated times. Cell  lysates were 
prepared, and subjected to Western blot analysis using anti-phospho-c-Jun, anti-phospho-
p65, anti-phospho-JNK, anti-phospho-ATF2, and anti-TAK1. The blots were stripped and 
re-probed using anti-tubulin antibodies to ensure equal loading and transfer. 
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Figure  3.18  S1P  abolishes  IL-1-induced  phosphorylation  of  STAT1  and  STAT2. 
Astrocytes were stimulated with 10 ng/ml IL-1 and 5 µM S1P for the indicated times. Cell 
lysates were prepared,  and analyzed by Western blotting using anti-phospho-STAT1 and 
anti-phospho-STAT2.  Blots  were stripped and re-probed using anti-tubulin  antibodies  to 
ensure equal loading and transfer. 
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10  and  RANTES  mRNA  expression,  the  phosphorylation  of  STAT1  and  STAT2  was 
analyzed  in  response  to  S1P  and  IL-1  (Figure  3.18).  IL-1  efficiently  stimulated  the 
phosphorylation  of  STAT1  and  STAT2  at  4  and  8  hours,  but  co-treatment  with  S1P 
completely abolished this  phosphorylation.  Since STAT1 and STAT2 phosphorylation is 
induced by interferon, we examined the mRNA expression of IFNβ in response to IL-1 and 
S1P (Figure  3.19).  Indeed,  IL-1  induced low levels  of  IFNβ (approximately  a  10  fold 
increase); however, S1P almost completely blocked this induction. In agreement with these 
results,  inhibition  of  new  protein  synthesis,  by  cycloheximide  (CHX),  eliminated  IL-1 
induced IP-10 mRNA expression (Figure 3.20 A). In contrast,  CHX enhanced RANTES 
mRNA expression, as has previously been reported  (Figure 3.20 B). To further substantiate 
the  hypothesis  that  S1P  inhibits  IP-10  and  RANTES  up-stream  of  IFNβ production, 
astrocytes were stimulated with S1P in conjunction with IFNα, IFNβ, and IFNγ (Figure 3.21 
A, B, C, and D). In contrast to S1P-mediated inhibition of IL-1- and TNFα-induced IP-10 
and RANTES mRNA expression, S1P enhanced IFNα, IFNβ, and IFNγ activation of IP-10 
and RANTES mRNA expression. Nevertheless, IFNγ was ineffective in inducing RANTES 
mRNA expression,  which  is  most  likely  due  to  the  fact  that  IFNγ is  only  capable  of 
stimulating STAT1/STAT1 homodimer formation,  and RANTES lacks the GAS element 
that  binds  STAT1/STAT1  homodimers.  Taken  together,  these  results  suggest  that  S1P 
suppresses IP-10 and RANTES mRNA expression via the inhibition of IL-1-induced IFNβ 
mRNA expression, and thus the subsequent STAT1 and STAT2 phosphorylation necessary 
for IP-10 and RANTES activation.
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Figure  3.19  S1P  represses  IL-1-induced  IFNβ mRNA  expression. Astrocytes  were 
stimulated with 10 ng/ml IL-1 and 5 µM S1P for 3 hours. RNA was isolated, and the mRNA 
expression  of  IFNβ was  analyzed  by  qPCR.  The mRNA expression  was  normalized  to 
GAPDH mRNA, and expressed as a ratio to untreated cells. A representative result from four 
separate experiments, which produced similar results, is shown. 
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Figure 3.20 New protein synthesis is required for IL-1-induced mRNA expression of 
IP-10.   Astrocytes were treated with 20  µg/ml cycloheximide (CHX) for 1 hour prior to 
stimulation with 10 ng/ml IL-1 and 5 µM S1P for 8 hours. RNA was isolated, and analyzed 
by qPCR. The mRNA mRNA expression of IP-10 (A) and RANTES (B) was normalized to 
GAPDH mRNA, and expressed as a ratio to untreated cells. The experiment was performed 
twice, and a representative is shown. 
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Figure  3.21  S1P  synergizes  with  exogenous  IFN  to  stimulate  IP-10  and  RANTES 
mRNA expression. Astrocytes were stimulated with 1000 u/ml IFNα, IFNβ, and IFNγ, as 
well  as 5  µM S1P for 8 hours. RNA was isolated,  and analyzed by qPCR. The mRNA 
mRNA expression of IP-10 (A) and RANTES (B) was normalized to GAPDH mRNA, and 
expressed as a ratio to untreated cells. The experiment was performed in triplicate, and a 
representative is shown. 
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3.4.8 TAK1 is required for S1P inhibition of STAT1 and STAT2 phosphorylation, as 
well as IP-10 and RANTES gene expression.
As NF-κB activation  is  necessary  for  IL-1-induced IP-10 and RANTES mRNA 
expression (Figures 3.15 and 3.16), but not for S1P inhibition, we assessed whether it is 
necessary for STAT1 and STAT2 phosphorylation. We stimulated astrocytes with IL-1 and 
S1P in the presence of the IKKα/β inhibitor (Bay11-7082), and subsequently analyzed the 
phosphorylation of STAT1 and STAT2 (Figure 3.22). Bay11-7082 abolished IL-1-induced 
phosphorylation of STAT1 and STAT2. Thus, NF-κB is not only necessary for IP-10 and 
RANTES mRNA expression,  but  also for  the IL-1-induced mRNA expression  of  IFNs, 
which leads to the phosphorylation of STAT1 and STAT2. In search for a target of S1P 
action, we turned our attention to TAK-1, which is needed for MAPK activation by IL-1 (, 
Figure  3.23 B).  We used a  specific  TAK1 inhibitor,  which  blocks  the activation  of  its 
downstream targets,  such as JNK and p38 (Figure  3.23 B).  Indeed,  the TAK1 inhibitor 
abolished the inhibitory effect of S1P on IL-1-induced STAT1 and STAT2 phosphorylation 
(Figure 3.23 A). More importantly, the TAK1 inhibitor also blocked S1P inhibition of IL-1 
stimulation of IP-10 and RANTES mRNA expression (Figure 3.24 A and B). In fact, S1P 
synergized with IL-1 in the presence of the TAK1 inhibitor. It is also important to note that 
the IL-1-induced mRNA expression of IP-10 and RANTES was significantly reduced by the 
TAK1 inhibitor, signifying the importance of TAK1-dependent signaling. These results were 
confirmed in TAK1-/- MEFs, which were un-responsive to IL-1 and S1P in regards to IP-10 
and  RANTES  mRNA  expression,  and  the  basal  level  of  IP-10  and  RANTES  mRNA 
expression was also significantly impaired in 
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Figure  3.22  Inhibition  of  IKKα/β by  Bay11-7082  abolishes  IL-1-induced 
phosphorylation of STAT1 and STAT2. Astrocytes were treated with 5 µM Bay11-7082 
inhibitor for 1 hour prior to stimulation with 10 ng/ml IL-1 and 5 µM S1P for 4 hours. Cell 
lysates were prepared and analyzed by Western blotting using anti-phospho-STAT1 and 
anti-phospho-STAT2. The blots were stripped and re-probed using antibodies to anti-tubulin 
to ensure equal loading and transfer. 
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Figure 3.23 TAK1 inhibitor reverses S1P suppression of IL-1-induced phosphorylation 
of STAT1 and STAT2.  Astrocytes were treated with 600 nM TAK1 inhibitor for 3 hours 
prior to stimulation with 10 ng/ml IL-1 and 5 µM S1P for 4 hours (A) or 15 minutes (B). 
Cell lysates were prepared and analyzed by Western blotting using anti-phospho-STAT1 and 
anti-phospho-STAT2 (A), as well as anti-phospho-p38 and anti-phospho-JNK (B). The blots 
were  stripped  and  re-probed  with  anti-tubulin  antibodies  to  ensure  equal  loading  and 
transfer. 
120
121
Figure  3.24  TAK1  inhibitor  blocks  S1P  suppression  of  IL-1-induced  IP-10  and 
RANTES mRNA expression. Astrocytes were treated with 600 nM TAK1 inhibitor for 3 
hours prior to stimulation with 10 ng/ml IL-1 and 5 µM S1P for 8 hours. RNA was isolated, 
and the mRNA expression of IP-10 (A) and RANTES (B) was analyzed by qPCR. The data 
were normalized to GAPDH mRNA expression, and expressed as a ratio to untreated cells. 
The experiment was performed in two separate experiments, and one is shown.
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Figure  3.25  mRNA  expression  of  IP-10  and  RANTES  is  completely  abolished  in 
TAK1-/- MEFs. TAK1 WT and TAK1 KO MEFs were stimulated with 10 ng/ml IL-1 and 1 
µM S1P for  8  hours.  RNA was  isolated,  and  the  mRNA expression  of  IP-10 (A)  and 
RANTES (B) was analyzed by qPCR. The data were normalized to GAPDH mRNA, and 
expressed  as  a  ratio  to  untreated  cells.  The  experiment  was  performed in  two separate 
experiments, and one is shown. 
124
125
these cells (Figure 3.25 A and B). These results suggest that TAK1 is necessary for IP-10 
and RANTES basal mRNA expression, the IL-1-induced mRNA expression, as well as the 
inhibition  of  STAT1  and  STAT2  phosphorylation  and  IP-10  and  RANTES  mRNA 
expression by S1P.
3.4.9 S1P induces hyper-phosphorylation of TAK1
Since TAK1 appears to be the key to the regulation of IP-10 and RANTES mRNA 
expression  by  S1P  and  IL-1,  we  investigated  the  effect  of  S1P  and  IL-1  on  the 
phosphorylation of TAK1, and several known targets of TAK1 (Figure 3.26). In astrocytes, 
IL-1  induced  rapid  and  transient  phosphorylation  of  TAK1  within  15  min,  while  co-
stimulation with S1P resulted in increased and sustained phosphorylation, lasting up to 2 
hours.  However,  the IL-1-induced phosphorylation  of  the downstream targets  of  TAK1, 
including  JNK,  p38,  ATF-2,  MKK3/6,  MKK4,  and  MKK7  were  unaffected  by  S1P. 
Furthermore,  the phosphorylation  of  MEKK1,  another  MAP3K kinase that  is  known to 
activate JNK , was also unaffected by S1P. These results suggest that S1P, via an unknown 
mechanism, specifically induces sustained hyper-phosphorylation of TAK1, which affects 
the IL-1-induced mRNA expression of IP-10 and RANTES.
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Figure 3.26 IL-1 and S1P activation of downstream targets of TAK1. Astrocytes were 
stimulated with 10 ng/ml IL-1 and 5  µM S1P for the indicated times. Cell  lysates were 
prepared and the same cell lysates were analyzed by Western blotting using anti-phospho-
TAK1 [Thr184/187], anti-IRAK1, anti-phospho-MKK7, anti-phospho-MKK4, anti-phospho-
MKK3/6, anti-phospho-MEKK1, anti-phospho-p38, anti-phospho-JNK, anti-phospho-ATF2, 
anti-p38, anti-TAK1, and anti-phospho-TAK1 [Ser412] antibodies. Blots were stripped and 
re-probed with anti-tubulin antibodies to ensure equal loading and transfer. 
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3.4.10 S1P inhibition of IP-10 involves the ISRE binding site within its promoter.
In order to gain insight on the mechanism of S1P-mediated inhibition, we utilized 
several  human IP-10 reporter  constructs  in  transient  transfection experiments in  primary 
human astrocytes (Figure 3.27). The truncated IP-10 reporter (TGL_IP-10) contains an ISRE 
and two NF-κB binding sites,  which are  known to be important  for IP-10 expression  . 
Indeed, in astrocytes, IL-1 induced the truncated IP-10 reporter, while S1P suppressed this 
induction (Figure 3.28 A). Furthermore, mutation of the ISRE site reduced the response to 
IL-1, and S1P was not able to inhibit IP-10 reporter activity; while, mutation of the second 
NF-κB site simply reduced the basal luciferase activity (Figure 3.28 B and C). Thus, these 
results imply that the ISRE site within the IP-10 promoter is crucial for the repression of 
IL-1-induced IP-10 mRNA expression by S1P. 
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Figure 3.27 Diagram of TGL-IP-10-Luc reporter, as well as the ISRE and κB2 mutants. 
pTGL-IP-10 contains the ISRE site, and the two NF-κB sites known to be important for 
IP-10 mRNA expression. pTGL-IP-10-ISRE contains a mutation in the ISRE binding site, 
and the pTGL-IP-10-κB2 Mut contains a mutation in the second NF-κB site. 
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Figure  3.28  The  ISRE  site  within  the  IP-10  promoter  is  required  for  the  S1P 
suppression of IP-10. Astrocytes were transiently transfected with pTGL-IP-10-Luc, TGL-
IP-10-ISRE-Luc, TGL-IP-10-kB2 Mut-Luc, and β-galactosidase as a control for transfection 
efficiency.  One  day  after  transfection,  cells  were  grown  in  1%  serum  overnight. 
Subsequently, cells were stimulated with 10 ng/ml IL-1 and 5 µM S1P for 8 hours, and then 
lysed. Luciferase activity was normalized to  β-galactosidase activity.  A representative of 
three separate experiments is shown. 
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3.5 DISCUSSION
Multiple  sclerosis  is  a  disease  of  the  central  nervous  system  characterized  by 
demyelination and axonal loss, as well as periods of remission and relapse. Demyelination is 
caused by an inflammatory response that detaches myelin from neurons, and cells such as 
microglia  and  astrocytes  exacerbate  the  situation  by  causing  glial  scarring.  This 
inflammatory response is primarily attributed to auto-reactive T cells. T cells are attracted to 
sites  of  inflammation  by  chemokines,  which  are  released  by  activated  microglia  and 
astrocytes. In particular, two T cell chemotactic chemokines, IP-10 and RANTES, have been 
found  to  be  increased  within  demyelinated  lesions  of  MS patients  .  Furthermore,  anti-
CXCL10 (IP-10) mAbs, and a RANTES variant (44AANA47-RANTES) both reduce disease 
onset and severity .  Thus, treatments that target these two chemokines may prove to be 
efficacious in treating MS patients. 
IL-1, the major pro-inflammatory cytokine of the brain, has been reported to increase 
a variety of chemokines, including IP-10 and RANTES, in the brain . Moreover, increased 
levels of IL-1 have also been associated with MS lesions . Interestingly, IL-1 also increases 
the expression and activity of SphK1, which is the enzyme that produces the bioactive lipid 
S1P by the phosphorylation of Sph . Here we show that S1P significantly inhibits IL-1-
induced IP-10 and RANTES mRNA expression, while augmenting IL-1-stimulated mRNA 
expression of IL-6, IL-8, and MIP-1β in primary human astrocytes. 
Interestingly, IL-6 and IL-8 are known to be primarily regulated by NF-κB , while 
IP-10  and  RANTES  are  primarily  regulated  by  STATs  binding  to  the  ISRE  sites 
(IRF9/STAT1/STAT2 heterotrimer) present in both promoters, and the GAS element (bind 
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STAT1/STAT1 homodimer) present in the IP-10 promoter. Here we show that while S1P 
activates NF-κB via inducing the phosphorylation of IKKα/β, the degradation of IκBα, and 
the  phosphorylation  of  p65,  NF-κB  is  not  important  for  the  repression  of  IP-10  and 
RANTES mRNA expression by S1P. However, NF-κB is indispensable for IL-1-stimulated 
IP-10 and RANTES mRNA expression, as the Bay11-7082 inhibitor abolishes both the IL-1 
induction of theses genes and the IL-1-induced phosphorylation of STAT1 and STAT2. In 
contrast to the activation of NF-κB, S1P abolishes IL-1 induced phosphorylation of STAT1 
and STAT2. S1P represses IL-1-induced STAT phosphorylation by inhibiting the production 
of IFN, which when released from the cells, binds to their cell surface receptors and activates 
the JAK/STAT pathway (Figure 3.29 and 3.30). These results indicate that S1P specifically 
targets  STAT regulated  chemokines,  such  as  IP-10 and RANTES,  for  inhibition,  while 
enhancing NF-κB dependent genes, such as IL-6 and IL-8.
Furthermore,  the  inhibition  of  IP-10  and  RANTES  mRNA  expression  by  S1P 
appears to be a general, non-cell-specific process, as S1P also blocks IL-stimulation of IP-10 
and RANTES mRNA expression in MEFs, HeLa, and U373 cells. In addition, the inhibition 
by  S1P is  not  cytokine  specific,  since  S1P also  quenches  IP-10 and RANTES mRNA 
expression stimulated by TNFα; thus, suggesting a common mechanism between IL-1 and 
TNFα. This common link is most likely TAK1, as the receptors for IL-1 and 
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Figure 3.29 Model  of  S1P suppression of  IL-1-induced IFN mRNA expression.  Our 
current model is that S1P binds to the S1P2 receptor, and through signaling from its receptor 
inhibits IFN mRNA expression at or above the level of TAK1. 
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Figure  3.30  Model  of  S1P  repressing  IL-1-induced  IFN  stimulation  of  IP-10  and 
RANTES mRNA expression. IL-1 induces IFN mRNA expression, IFNs activate the JAK-
STAT pathway, and phosphorylated STAT1 and STAT2 bind to the ISRE elements within 
the IP-10 and RANTES promoters. However, when S1P is present, it represses IL-1-induced 
IFN production,  which  represses  STAT phosphorylation,  and  thus  IP-10  and RANTES 
mRNA expression. 
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TNFα utilize  the  MyD88  adaptor  protein  to  activate  TAK1.  Accordingly,  the  TAK1 
inhibitor  abolishes  S1P-induced  repression  of  IP-10  and  RANTES  mRNA  expression. 
Moreover,  the  TAK1  inhibitor  also  blocked  S1P  inhibition  of  IL-1-stimulated  STAT 
phosphorylation. Since stimulation with exogenous IFN synergizes with S1P to stimulate 
IP-10 and RANTES mRNA expression, it appears that S1P is regulating TAK1 up-stream of 
IFN  production.  Furthermore,  S1P  enhances  and  prolongs  endogenous  TAK1 
phosphorylation by IL-1. This suggests that S1P may modify TAK1 in such a way that it 
fails  to  dissociate  from  the  TRAF6/IRAK  complex,  and  therefore,  becomes 
hyperphosphorylated by IRAK. 
In conclusion, our data indicate that S1P specifically targets T cell chemokines, IP-10 
and RANTES, while increasing neutrophil and macrophage chemokines, such as IL-8 and 
MIP-1β, as well as IL-6. In addition, inhibition by S1P occurs via a general mechanism that 
leads  to  the  inhibition  of  IFN  production,  and  the  subsequent  STAT1  and  STAT2 
phosphorylation. Due to the fact that the major pathology of MS is due to autoreactive T 
cells  infiltrating the brain  and causing inflammation  induced demyelination,  a  treatment 
harnessing the T cell inhibitory effects of S1P would prove to be successful in MS treatment. 
In  fact,  the  S1P analog  FTY720,  which  when  phosphorylated  by  SphK2  in  vivo is  an 
effective  S1P  receptor  agonist  (for  S1P1,  S1P3,  S1P4,  and  S1P5)  ,  reduces  the  rate  of 
recurrence and gadolinium-enhanced (Gd (+)) lesions in MS patients during phase II clinical 
trials,  and  is  currently  in  phase  III  trials  .  However,  the  exact  mechanism of  FTY720 
mediated suppression of MS recurrence is not yet known. Therefore, as FTY720 mimics 
S1P, we propose that the mechanism described here of S1P suppression of IL-1-induced 
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IP-10 and RANTES mRNA expression, may be similar to that utilized by FTY720 to reduce 
MS lesions.
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CHAPTER 4 
GENERAL DISCUSSION AND FUTURE DIRECTIONS
Chronic inflammation within the brain incites multiple CNS diseases, including MS, 
Alzheimer’s,  Parkinson’s,  HIV-associated  dementia,  and  even  tumors  .  The  glial  cells, 
namely microglia and astrocytes, are the main culprits of inflammation within the brain, and 
thus CNS disease  progression.  Although,  resting astrocytes  are  crucial  for  normal  brain 
functions, such as secreting neurotrophic factors, glutamate consumption, and functioning as 
a  necessary  component  of  the  BBB  .  Microglia  are  not  only  important  for  immune 
surveillance,  but  also  for  programmed  removal  of  neural  cells  during  embryonic 
development  .  However,  upon injury  or  immunological  insult,  astrocytes  and  microglia 
become activated, and secrete a multitude of pro-inflammatory factors, such as cytokines and 
chemokines, cytotoxic factors such, as nitric oxide, and form glial scars that obstruct axonal 
regeneration . 
IL-1  is  the  major  pro-inflammatory  cytokine  in  the  brain,  and  is  released  from 
activated microglia and astrocytes. IL-1 stimulation of astrocytes has been shown to incite 
proliferation   and  astrogliosis  .  Moreover,  IL-1  stimulation  leads  to  the  expression  of 
cytokines, such as IL-6 and TNF-α, chemokines, including MIP-1α, MIP-1β, MCP-1, IL-8, 
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IP-10, and RANTES (Chapter 3), growth factors, consisting of bFGF, NGF, VEGF, and 
PDGF, and matrix metalloproteinases, specifically MMP9 . In addition to MMPs, IL-1 also 
increases  the  expression  of  the  components  of  another  matrix  remodeling  system,  the 
plasminogen activator system . 
The plasminogen activator system is comprised of two activators uPA and tissue 
tPA, and their inhibitors PAI-1, 2, and 3, and the uPA receptor, uPAR. uPA, which when 
bound to uPAR attains its own protease activity,  and tPA (which is primarily found in the 
blood as a clot dissolving enzyme) convert inactive plasminogen into plasmin, which is a 
serine protease with a broad range of specificity. IL-1 activation of these matrix remodeling 
proteases is significant, since high levels of IL-1 have been shown to be secreted by tumor 
cells,  such as glioblastoma . Glioblastoma multiforme is the most invasive primary brain 
tumor, and as a result all of the current treatments are unsuccessful. 
To establish a link between glioblastoma invasion and increased expression of the 
components of the plasminogen activator system, we investigated the mRNA and protein 
expression of uPAR and PAI-1 in glioblastoma cells upon stimulation with IL-1 (Chapter 2). 
In addition,  since IL-1 is  known to stimulate  the expression and activity of SphK1, the 
enzyme that produces S1P, we also studied the effects of S1P on the components of the 
plasminogen activator system. We found that S1P and IL-1 additively increased the mRNA 
expression of uPAR and PAI-1,  while uPA was unaffected.  Furthermore,  S1P and IL-1 
increased the in vitro invasion of U373 cells, which was abolished in the presence of siRNA 
to PAI-1 and uPAR. This suggests a direct connection between expression levels of both 
uPAR and PAI-1 and the invasion of glioma cells. Interestingly, increased levels of PAI-1 
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and  SphK1  are  indicators  for  a  poor  prognosis  of  survival  for  glioblastoma  patients  . 
Therefore, increased levels of IL-1, and thus SphK1 and S1P, increase the expression of 
matrix remodeling proteases, and thereby increase the invasion of glioblastoma cells. 
While the roles of S1P, and IL-1, in cancer progression are well-established, the roles 
that S1P may play in other CNS diseases, such as MS, are unexplored. Conversely, IL-1 is a 
well known instigator and promoter of MS. In fact, increased levels of IL-1 expression have 
been found in MS lesions , chronic exposure to IL-1 can lead to demyelination in rat, and 
inhibiting IL-1 can  reduce  the disease  in  animals  .  Moreover,  IL-1 has  been  shown to 
increase the expression of a variety of chemokines, which then recruit immune cells to the 
sites of inflammation. Specifically, IL-1 has been shown to increase the mRNA expression 
of IP-10 and RANTES, two T cell chemotactic chemokines. T cells are responsible for the 
major pathology of MS, and levels of RANTES and IP-10 are elevated in MS lesions . Since 
IL-1 is also known to increase the expression of SphK1, and its product S1P has never been 
studied in  regards  to MS,  we investigated the effect  of  S1P on IL-1-induced IP-10 and 
RANTES mRNA expression in primary human astrocytes (Chapter 3). S1P significantly 
repressed  IL-1  stimulated  IP-10 and  RANTES mRNA expression,  while  synergistically 
increasing  IL-1-induced  IL-8,  IL-6,  and  MIP-1β mRNA  expression.  The  obvious 
discrepancy in the regulation of these two sets of chemokines/cytokines by S1P is likely due 
to  their  promoter  regulation.  Indeed,  the  expression  of  both  IL-8  and  IL-6  is  NF-κB 
dependent, while the expression of RANTES and IP-10 is known to be primarily regulated 
by  STATs.  Interestingly,  S1P  activates  NF-κB,  but  inhibits  the  IL-1-induced 
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phosphorylation of STAT1 and STAT2 by preventing the production of IFNβ. Moreover, 
S1P  induces  the  prolonged  hyperphosphorylation  of  TAK1.  These  results  indicate  a 
mechanism by which S1P effectively inhibits the mRNA expression of two potent T cell 
chemokines, IP-10 and RANTES. Since IP-10 and RANTES are known to promote the onset 
and progression of MS , treatments mimicking the inhibitory effects of S1P may prove to be 
therapeutic for MS patients. 
Currently, an oral S1P receptor agonist (for all S1P receptors except S1P2), FTY720 
(Fingolimod), reduces the rate of recurrence and gadolinium-enhanced (Gd (+)) lesions in 
MS patients during phase II  clinical  trials,  and is currently being evaluated in phase III 
trials . FTY720 is active (FTY720-P) when phosphorylated by SphK2 in vivo , and FTY720-
P then binds to and causes the internalization, degradation, and decreased mRNA expression 
of the S1P receptors . Its effects on MS lesions have been credited to the arrest of T- and B- 
lymphocytes in secondary lymph nodes by FTY720 internalization of the S1P1 receptor . 
However, FTY720 easily crosses the BBB, and collects in the brain parenchyma ; thus, it has 
been proposed that FTY720 exerts its affects beyond the immune system, and may play a 
neuro-protective role . Indeed in EAE models, FTY720-P decreases permeability of the BBB 
and affects glial repair mechanisms, which restores nerve function . In addition, FTY720-P 
reduces  the  expression  of  pro-inflammatory  cytokines  and  chemokines  .  However,  the 
precise  mechanism of  FTY720  mediated  suppression  of  MS lesions  is  not  yet  known. 
Therefore, we propose that the FTY720 mediated suppression of chemokines and MS lesions 
may function by a similar mechanism to that of S1P. Furthermore, treatment with FTY720 
can  also  result  in  several  adverse  side  effects,  including  diarrhea,  nasopharyngitis, 
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bradycardia, and clinically asymptomatic increased levels of liver enzymes ; thus, S1P may 
be a natural alternative for treatment of MS. 
Nevertheless, the most fascinating questions revolve around the regulation of IFNβ 
by S1P. Specifically, since S1P effectively inhibits the production of IFNβ in response to 
IL-1,  it  may also suppress the production of  IFN in response to infection with a virus. 
Moreover, it raises the possibility that a virus exists that either expresses SphK, or activates 
endogenous SphK to block host induction of IFN. Furthermore, S1P is anti-apoptotic and a 
well  known promoter of  cancer progression and metastasis,  but  could the anti-apoptotic 
effects of S1P be related to its inhibitory effect on the pro-apoptotic IFN? Given that S1P 
also represses chemokine induction in response to TNFα, it may be of interest to further 
investigate this mechanism of regulation; although it seems likely that the S1P regulation of 
TNFα  involves the same, or a similar mechanism to that of IL-1. However, all of these 
questions remain to be investigated in future projects. Meanwhile, this dissertation expands 
on the existing knowledge that IL-1 and S1P increase the mRNA and protein expression of 
uPAR and PAI-1,  and that  this  increase in  expression is  associated with an increase in 
glioma cell  invasion.  Moreover,  this  thesis  describes  a  novel  mechanism by which S1P 
inhibits  IL-1-induced  IP-10  and  RANTES  mRNA  expression.  Thus,  this  dissertation 
identifies  new thearapeutic  targets  for  two  devastating  CNS diseases,  glioblastoma and 
multiple sclerosis. 
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APPENDIX A
REGULATION AND FUNCTIONS OF SPHINGOSINE KINASE IN THE BRAIN
A.1 ABSTRACT
It  has long been known that  sphingolipids,  especially  sphingomyelin,  a  principal 
component of myelin, are highly enriched in the central nervous system and are structural 
components of all eukaryotic cell membranes. In the last few years, substantial evidence has 
accumulated from studies of many types of cells  demonstrating that  in addition to their 
structural roles, their breakdown products form a new class of signaling molecules.  with 
potent  and  myriad  regulatory  effects  on  essentially  every  cell  in  the  body.  While  the 
sphingolipid metabolites sphingosine and its precursor ceramide have been associated with 
cell  growth  arrest  and  apoptosis,  sphingosine-1-phosphate  (S1P)  enhances  proliferation, 
differentiation, and cell survival as well as regulates many physiological and pathological 
processes. The relative levels of these three interconvertible sphingolipid metabolites, and 
thus cell fate, are strongly influenced by the activity of sphingosine kinases, of which there 
are  two  isoforms,  designated  SphK1  and  SphK2,  the  enzymes  that  phosphorylate 
sphingosine to produce S1P. Not much is yet known of the importance of S1P in the central 
nervous system. Therefore, this review is focused on current knowledge of regulation of 
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SphK1 and SphK2 on both transcriptional and posttranslational levels and the functions of 
these isozymes and their product S1P and its receptors in the central nervous system.
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A.2 INTRODUCTION
The  interconvertible  sphingolipid  metabolites,  ceramide,  sphingosine,  and 
sphingosine-1-phosphate (S1P), are now recognized as important bioactive mediators that 
regulate  many  cellular  and  physiological  processes  .  To  highlight  just  a  few of  these, 
ceramide and sphingosine have been shown to be involved in cell cycle arrest and apoptosis , 
while S1P has been implicated in cell proliferation, survival, migration, angiogenesis, and 
differentiation .  The relative  levels  of  ceramide and sphingosine compared to S1P,  also 
known as the sphingolipid rheostat, is critical in determining cell fate . Thus, increased levels 
of S1P can protect against apoptosis mediated by increases in cellular ceramide, a major 
response to stress . The synthesis and metabolism of sphingolipids was recently discussed in 
an excellent review  and will not be discussed here. However these pathways are shown in 
Figure A.1 and the reader is referred to this comprehensive review for detailed information. 
S1P can act intracellularly to increase DNA synthesis and suppress apoptosis and regulate 
calcium mobilization , although the intracellular targets of S1P are still elusive. The most 
well-characterized functions of S1P are mediated by binding to five ubiquitously expressed 
G protein-coupled receptors (named S1P1-5) . The S1P receptors couple to a variety of G 
proteins  with  varying  affinities  for  different  effector  molecules  that  activate  numerous 
downstream  signaling  pathways  .  Thus,  depending  on  the  spectrum  of  S1P  receptors 
expressed in  a  given  cell  type,  S1P can  activate  various  pathways regulating numerous 
important cellular and physiological functions . Sphingosine kinases (SphKs), the enzymes 
that produce S1P by phosphorylating sphingosine, are essential elements in the regulation of 
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Figure A.1 Abbreviated model showing pathways for production and synthesis of S1P, and 
its actions through S1P receptors expressed in the brain. 
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S1P levels, and hence levels  of its precursors, sphingosine and ceramide. There are two 
isoforms  of  SphK,  SphK1  and  SphK2,  that  have  different  properties  and  subcellular 
locations , suggesting that they have distinct biological functions, although they may be able 
complement each other for some vital functions since production of S1P is critical for brain 
and cardiovascular system development . Many studies have established that expression of 
SphK1 is associated with cell survival and proliferation. Presumptive evidence suggests that 
sphk1 may be  an  oncogene:  overexpression  of  SphK1 in  NIH 3T3 cells  enhances  foci 
formation, colony growth in soft agar, and tumor formation in SCID mice ; MCF7 human 
breast  cancer  cells  overexpressing  SphK1 produce  larger  and more  abundant  tumors  in 
xenografts ; and SphK1 is expressed at high levels in many types of cancers . The biological 
functions of SphK2 are not yet clearly defined and appear to vary depending on the cell type. 
However, when overexpressed, SphK2 generally acts as a “bad” kinase and induces cell 
cycle arrest and apoptosis . Because there is such a paucity of information on the role of 
SphKs and S1P at the molecular level in the central nervous system, this review will first 
focus on current knowledge of transcriptional and posttranscriptional regulation of SphKs 
gleaned from studies in various types of cells. 
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A.3.1 STRUCTURE AND LOCALIZATION OF SPHINGOSINE KINASES
In humans, the sphk1 gene is located on chromosome 17 (17q25.2), while the sphk2 
gene is on chromosome 19 (19q13.2). SphK1 and SphK2 are highly homologous and contain 
five conserved domains, one of which includes the conserved diacylglycerol kinase ATP 
binding domain . Although SphK1 and SphK2 display 80% amino acid sequence similarity , 
they differ in their central regions and N termini. SphK1 lacks transmembrane domains or 
identifiable signal sequences and is mainly cytosolic . SphK1 is abundantly expressed in 
adult mouse heart, spleen, lung, and brain, whereas SphK2 expression is highest in brain, 
kidney, and liver . SphK2 is about 240 amino acids longer than SphK1 at its N terminus and 
contains  several  transmembrane  domains  .  In  addition,  SphK2  possesses  a  nuclear 
localization  signal  within  its  N terminal  region,  which  when  mutated,  prevents  it  from 
entering  the  nucleus  and  inhibiting  DNA  synthesis  .  Unlike  SphK1,  which  is  mainly 
localized to the cytosol in all cells, SphK2 localization is cell type-specific. For example, in 
HEK 293 cells, SphK2 can be detected in the plasma membrane, mitochondria, ER, Golgi, 
and in the cytosol , whereas, in COS7, HeLa, MCF7, and NIH 3T3 cells, it is predominantly 
localized to the nucleus . 
A.3.2. ACTIVATION OF SPHINGOSINE KINASES 
A broad range of external stimuli has been reported to activate SphK1, among which 
are  various  growth  factors  including  platelet-derived  growth  factor  (PDGF),  epidermal 
growth  factor  (EGF),  vascular  endothelial  growth  factor  (VEGF),  nerve  growth  factor 
(NGF), basic fibroblast growth factor (bFGF), transforming growth factor beta (TGFβ), and 
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insulin-like  growth  factor-1  (IGF-1),  cytokines  such  as  TNF-α and  interleukins,  and 
hormones (estradiol and prolactin) (reviewed in ). Many of these stimuli activate SphK1 in a 
biphasic manner. That is to say, the first phase of activation is rapid (minutes) and transient, 
most  likely  via  post-translational  modifications  that  increase  enzymatic  activity  and  its 
translocation to the plasma membrane where its substrate sphingosine resides, and a second 
phase of activation over the next 24 h that entails upregulation of transcription. Much less is 
known about regulation of SphK2 activity. 
A.3.3. POST-TRANSLATIONAL ACTIVATION OF SPHK1 AND SPHK2 
Several  SphK1 interacting proteins  have been identified by the yeast  two-hybrid 
approach . Although some have been shown to interact with SphK1 in mammalian cells, 
none  have  yet  been  implicated  in  regulation  of  SphK1  activity  or  S1P  production. 
Crosslinking  of  the  high  affinity  IgE  receptor  (FcεRI)  on  mast  cells  activates  SphK1, 
increasing production of  S1P,  which is  secreted and regulates  mast  cell  functions in  an 
autocrine or paracrine manner by binding to S1P receptors. Recently, activation of SphK1 
was  shown to  be  due  to  direct  interaction  with  Lyn  tyrosine  kinase  .  This  interaction 
explicitly enhanced the enzymatic activities of both SphK1 and Lyn, although SphK1 was 
not phosphorylated by Lyn. More recently, SphK2 was also reported to be activated upon 
FcεRI crosslinking . In addition, Fyn, another Src protein tyrosine kinase, is also essential for 
SphK1 and SphK2 activation, since mast cells  from Fyn deficient mice exhibit impaired 
SphK1 and SphK2 enzyme activity and S1P production . However, neither SphK, nor SphK2 
are  substrates  for  Fyn.  Rather,  activation  of  SphK1 by Fyn involves  the adapter  Grb2-
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associated  binder  2  and  phosphatidylinositol  3-kinase,  but  activation  of  SphK2  is 
independent of this pathway . 
In contrast, some activators require Ca2+ to stimulate SphK. For instance, activation 
of  SphK1 by platelet  derived growth factor BB (PDGF-BB) is  blocked by chelation of 
intracellular  Ca2+ with  BAPTA-AM .  Specifically,  PDGF  activation  of  SphK1  requires 
phosphorylation  of  the  PDGF  receptor  on  tyrosine-1021,  which  is  necessary  for  the 
subsequent  association  with PLCγ,  thus leading to  production  of  InsP3 and downstream 
mobilization  of  calcium .  Moreover,  it  has  been  proposed that  SphK1 contains  several 
putative Ca2+/calmodulin binding sites . In agreement, translocation of SphK1 to the plasma 
membrane  induced  by  the  PKC activator  phorbol  ester  is  inhibited  by  the  loss  of  the 
functional calmodulin binding site . In spite of these findings, direct activation of SphK1 by 
Ca2+ or calmodulin has not been detected. 
EGF is one of the most potent, and most well studied, activators of SphK1. In MCF7 
cells, EGF stimulates SphK1 activity and induces its translocation from the cytosol to the 
plasma membrane . A novel EGF pathway involving sequential activation of c-Src, PKCδ, 
and subsequent activation and translocation of SphK1 to the plasma membrane was recently 
described in glioblastoma cells . Several lines of evidence suggest that PKCδ and SphK1 
may be downstream targets of EGF-activated c- Src in these glioma cells: (i) EGF induced 
rapid  phosphorylation  and  translocation  of  PKCδ to  the  plasma  membrane,  which  was 
blocked by the Src inhibitor PP2; (ii) EGF also induced translocation of SphK1 to the plasma 
membrane which was blocked by inhibition of c-Src and by downregulation of PKCδ; and 
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(iii)  downregulation  of  PKCδ and SphK1 abolished EGF-induced plasminogen activator 
inhibitor-1 (PAI-1) expression. It is important to note that although, the high expression of 
EGFR alone is not a prognostic marker in gliomas, patients expressing high levels of both 
EGFR and PAI-1 have a shorter overall survival prognosis . Thus, our recent results suggest 
that SphK1 is a downstream target of PKC. that is indispensable for PAI-1 upregulation by 
EGF,  and  might  have  important  implications  for  glioma  invasiveness.  Interestingly,  in 
primary  cytotrophoblasts,  the PI3K inhibitor  LY294002  blocked EGF-stimulated  SphK1 
activity, indicating the possible involvement of the PI3K/Akt pathway . Altogether, these 
studies suggest that EGF might utilize diverse signaling pathways to rapidly enhance SphK1 
activity. Additionally, EGF induced sustained activation of SphK1 that lasted for 24 hours. 
Similar sustained activation of SphK1 was also described in both primary human fibroblasts 
and in WI-38 fibroblasts in response to TGFβ, suggestive of an increase in transcription . 
NGF and bFGF also incite persistent activation of SphK1 in pheochromocytoma PC12 cells; 
however, EGF and IGF-1 only transiently stimulate SphK1 in these cells . Moreover, NGF 
instigates  translocation of SphK1 to the plasma membrane and local  production of S1P, 
which differentially activates the S1P1 and S1P2 receptors . While the precise mechanism of 
SphK1 activation by NGF is still not known, it is mediated by the TrkA tyrosine kinase 
receptor for NGF , which activates the Ras/ERK, PI3K/Akt, and PLCγ pathways . In T24 
bladder tumor cells, activation of the tyrosine kinase VEGF receptor by VEGF, a potent pro-
angiogenic growth factor, induces phosphorylation and activation of PKC via Flk-1, which 
in turn transiently activates SphK1 by direct phosphorylation . 
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The protein kinase C activator,  phorbol  12-myristate  13-acetate  (PMA),  also has 
been shown to transiently stimulate SphK1 by inducing PKC-dependent phosphorylation and 
translocation to the plasma membrane . Furthermore, stimulation of SphK1 by PMA, as well 
as the pro-inflammatory cytokine TNF-α, requires its phosphorylation on Ser225 . SphK1 
possesses a docking site for ERK1/2  and both ERK1 and ERK2 phosphorylate SphK1 at 
Ser225 , which is crucial for its translocation to the plasma membrane . This translocation is 
also important for its oncogenic signaling [41]. TNFα, and interleukin-1β (IL-1β) have also 
been shown to transiently increase SphK1 enzyme activity in A549 epithelial lung carcinoma 
cells . This activation does not stem from increases in its mRNA or protein levels; therefore, 
it is most likely due to a phosphorylation event similar to that described above. 
As SphK1 has been identified as an important pro-survival factor, it seems logical 
that its activity or expression might be regulated by other pro-survival components. One of 
these is Bcl-2 which was initially described as an oncogene in follicular lymphomas , and 
later found to be an anti-apoptotic protein that promotes cell survival . Interestingly, Bcl-2 
expression protects SphK1 from proteolysis induced in response to DNA damaging drugs . 
Additionally,  overexpression of Bcl-2 in A-375 human melanoma cells  increased SphK1 
enzyme activity, as well as its expression . Of note, SphK1 mediates BCR/ABL-induced 
upregulation of another anti-apoptotic protein Mcl-1 in chronic myeloid leukemia cells. In 
these cells, SphK1 expression and activity are upregulated by BCR/ABL via the ERK1/2, 
PI3K, and JAK2 pathways . A novel “criss-cross” transactivation mechanism important for 
proliferation that involves activation of SphK1 by 17β-estradiol (E2) has also been reported . 
In MCF7 human breast cancer cells, E2 binding to the estrogen receptor activates SphK1 and 
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increases  S1P  production.  Subsequently,  S1P  is  secreted  and  signals  through  the  S1P3 
receptor to increase metalloproteinase activity and production of EGF which then activates 
the EGF receptor . More recently, the hormone prolactin as well as E2 were also reported to 
biphasically  activate  SphK1 in  MCF-7 cells  .  The  initial  activation  of  SphK1 occurred 
rapidly after stimulation, followed by a much later increase in mRNA and protein expression 
and both phases of activation were ablated by MEK and PKC inhibitors . Moreover, the 
increase  in  the  proliferation  and  migration  in  response  to  either  E2 or  prolactin  was 
significantly reduced by downregulating SphK1 expression,  suggesting that activation of 
SphK1 is critical for these responses. 
Very few studies have examined the mechanism of activation of SphK2. In addition 
to activation of SphK2 by crosslinking of FcεRI , EGF-induced activation of SphK2 was 
observed in HEK 293 and MDA-MB-453 breast cancer cells . EGF induced migration of 
MDA-MB-453 cells was decreased by knock-down of either SphK1 or SphK2, suggesting 
that activation of both isozymes by EGF contributes independently to the motility responses 
in these cells. In a follow-up study, it was shown that activation of SphK2 induced by EGF 
resulted from EGFR-mediated ERK1/2-depenent phosphorylation of SphK2 . Site-directed 
mutagenesis indicated that hSphK2 is phosphorylated on Ser351 and Thr578 by ERK1 and 
that phosphorylation of these residues is important for EGF-stimulated migration of MDA-
MB-453 cells . 
Lastly,  it  was recently shown that PMA-induced phosphorylation of SphK2 on a 
putative  nuclear  export  sequence  (NES)  located  in  the  central  region  of  the  protein 
stimulated CRM1-mediated export from the nucleus to the cytosol . Furthermore, mutation 
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of two serine residues (Ser-419 and Ser-421) phosphorylated within this NES-like motif 
abolished SphK2 export. Thus, posttranslational modification via phophorylation of SphK2 
may be an important regulator of its activity and localization. 
A.3.4 TRANSCRIPTIONAL REGULATION OF SPHK1
To date, a great deal of our knowledge of the regulation of the  sphk1 gene stems 
from studies that were first performed in rodent cells. The rat sphk1 gene contains a 3.7 kb 
CpG island,  within  which  there  are  six  transcription  start  sites,  potentially  yielding  six 
alternative first exons; thus indicating that multiple splice variants of the rat sphk1 gene exist 
(sphk1a-f) . In the brain, the hypomethylated region of sphk1a is in the 5’ end of the CpG 
island,  and  a  tissue-dependent,  differentially  methylated  region  (T-DMR)  is  situated 
approximately 800 bp upstream of the sphk1a first exon. The T-DMR is hypomethylated in 
the brain, where sphk1a is the sole isoform. In contrast, the T-DMR is hypermethylated in 
the heart where sphk1a, as well as the other isoforms, is not expressed. These results suggest 
that  hypermethylation  of  the  T-DMR is  associated  with  sphk1a suppression.  Moreover, 
several endogenous antisense transcripts to sphk1, termed Khps1, have also been described . 
Of these,  Khps1a spans the T-DMR within the CpG island, and its expression induces the 
demethylation  of  CG sites within the T-DMR. Interestingly,  the expression of  sphk1 or 
Khps1 is  mutually  exclusive,  suggesting  that  the  CpG  island  regulates  the  intrinsic 
expression of sphk1. 
Little  is  known  of  the  regulation  of  SphK1 expression  but  several  transcription 
factors that regulate the sphk1 gene have been identified. The 55-bp fragment localized in 
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front  of  exon  1d  mediates  NGF induction  of  sphk1 gene  transcription  .  This  fragment 
contains one activator protein-2 (AP-2), and two specificity protein 1 (Sp1) binding sites. 
Interestingly, the proximal Sp1 site, and not the distal Sp1 site, is required for the intrinsic 
expression of the rat sphk1 gene. However, analysis of the 5’ flanking promoter region of the 
human  sphk1 gene  revealed  that  a  300 bp fragment  containing one Sp1 and two AP-2 
binding motifs,  effectively  mediates  sphk1 transcription  upon PMA treatment  in  human 
megakaryoblastic  leukemia MEG-01 cells  (Figure  A.2)  .  Moreover,  an unknown protein 
other than AP-2 binds to the AP-2 binding motifs of the promoter. Furthermore, MEK and 
PKC inhibitors also prevented the sphk1 promoter activity induced by PMA. These results 
imply that the PMA-induced sphk1 gene expression is mediated by transcription factors that 
are activated by the PKC and ERK signaling pathways. 
Histamine also upregulates SphK1 expression in endothelial cells via the PKC and 
ERK pathways and requires  the AP-2 and Sp1 binding motifs  of the  sphk1 gene .  The 
importance of these binding motifs in the transcriptional regulation of sphk1 was solidified 
by the observations that increased promoter activity induced by prolactin and GDNF also 
utilized the AP-2 and Sp1 binding motifs in MCF-7 cells  and TGW human neuroblastoma 
cells . Moreover, upregulation of SphK1 expression by prolactin also 
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Figure A.2 Regulatory elements within the 5’ flanking region of the sphk1 gene. See text 
for more details.
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required STAT5 activation, while GDNF induced transcription through the PI3K pathway in 
addition to the ERK1/2 pathway. 
Subjecting  glioma  cells  to  hypoxic  stress  activates  SphK1  and  increases  its 
expression, effects that may be important in more hypoxic areas in the center of a brain 
tumor . The increase in SphK1 activity resulted in increased intracellular S1P production and 
secretion.  Hypoxia  is  known  to  enhance  stability  of  hypoxia-inducible  factors  (HIFs), 
transcription factors that bind to hypoxia response elements (HREs) and regulate hypoxia-
inducible genes (Figure A.2). In this regard, the sphk1 5’ flanking region possesses multiple 
putative HRE sites, and a reporter construct containing 3124 bp upstream of the transcription 
start site conferred response to hypoxic stress . Furthermore, HIF-1α and HIF-2α both bind 
exclusively  to  a  region  within  the  5’  flanking  region  that  contains  an  evolutionarily 
conserved HRE site. Notably, HIF-2α, and not HIF-1α, activates transcription of the sphk1 
gene  under  hypoxic  conditions  .  In  contrast  to  sphk1,  sphk2 transcriptional  regulation 
remains unexplored. 
A.3.5 FUNCTIONS OF SPHINGOSINE KINASES AND S1P IN THE BRAIN
The  brain  is  the  organ  that  contains  the  highest  concentration  of  S1P  .  During 
pathological conditions, such as brain injury or stroke, local concentrations of S1P may be 
further increased as S1P could be released from platelets in blood clots . Moreover, high 
expression levels of SphK1 have been correlated with decreased rates of survival for patients 
diagnosed with glioblastoma multiforme,  the most  invasive primary brain tumor .  SphK 
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activity  and S1P also  protect  cultured mesencephalic  neurons against  glutamate-induced 
neurotoxicity . 
There have been contradictory reports as to which SphK isoform is predominantly 
responsible for S1P production in normal brain tissue . One study has reported that SphK1 is 
the primary isoform in mouse brain , and is highly abundant in the cerebellum where it is 
located within the dendrites and dendritic spines of Purkinje cells . As discussed above, it 
seems most likely that both SphK1 and SphK2 are expressed in the brain and probably even 
within the same cells, as neither of the single SphK knockout mice display a remarkable 
CNS phenotype, while the double SphK1-SphK2 knockout mice have a severe brain defect . 
A substantial presence of SphK2 in the brain is more consistent with reports on the 
effects of the potent immunosuppressant FTY720 in the CNS. It is well  established that 
FTY720 is phosphorylated in vivo by SphK2, converting it to a S1P mimetic and potent S1P 
receptor agonist that accumulates in CNS white matter . In experimental allergic encephalitis 
models,  FTY720-phosphate  affects  the  blood-brain  barrier  and  glial  repair  mechanisms, 
which restores nerve function . Moreover, FTY720 seems to be a highly promising drug for 
treatment of relapsing multiple sclerosis and is currently in Phase III trials . 
Thus, clearly both SphK1 and SphK2 must be expressed in the brain, but far more is 
known about the functions of SphK1 there. bFGF, another growth factor present in brain, 
induced secretion of  S1P from cerebellar  astrocytes,  which was prevented by inhibiting 
SphK1 . S1P in turn increased DNA synthesis and activated ERK1/2 via one of its Gi/Go 
coupled receptors, of which S1P1, S1P2, and S1P3 are expressed in cerebellar astrocytes. S1P 
also signals inside out in hippocampal neurons to facilitate glutamate secretion induced by 
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secretagogues  and  SphK1  may  be  involved  in  the  underlying  regulation  of  synaptic 
transmission . SphK1 is not only capable of regulating functions in the brain via its product 
S1P,  but  also  through  corresponding  effects  on  intracellular  levels  of  its  substrate 
sphingosine. Thus, conversion of sphingosine to S1P can also regulate calcium levels in 
neurons as sphingosine inhibits voltage-operated calcium channels (VOCC), which prevents 
calcium entry in response to depolarization . In agreement, expression of SphK1 in GH4C1 
rat pituitary cells reduced inhibition of the VOCC by sphingosine . 
An interesting observation was made that SphK1 interacts with and is activated by 
neural  plakophilin-related  armadillo  repeat  protein  (δ-catenin/NPRAP)  in  hippocampal 
neurons . Moreover, a SphK inhibitor decreased δ-catenin/NPRAP-dependent neuronal cell 
migration  .  S1P also  plays  an  important  role  in  motility  of  glioblastoma cells  ,  and as 
previously  mentioned,  is  critical  for  the  process  of  invasion.  Furthermore,  S1P  signals 
through S1P1, S1P2, and S1P3 to stimulate glioma cell proliferation, and activation of S1P1 
and S1P3 also amplifies glioma migration and invasion . 
A.3.6 S1P RECEPTORS IN THE CNS
Although receptors for S1P are abundant in the central nervous system, only a few 
studies have addressed cell-specific functions of S1P via its receptors, and most of these 
Table A.1 S1P receptors and functions in neurons and glial cells.
S1P 
Receptors
Function in the Brain Reference
Activates neurite outgrowth/extension in neurons 
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S1P1 Depolarization-induced glutamate release is dependent 
on SphK1, S1P formation, and subsequent S1P1 
activation
Migration of neural stem cells toward a site of spinal 
cord injury 
Mediates stimulation of ERK/Egr-1/FGF-2 in C6 glioma
Mediates ERK activation in astrocytes
Promotes astrocyte motility
Mediates PDGF-induced mitogenesis of 
oligodendrocyte precursors
S1P2
Inhibits neurite extension in neurons
Maintenance of vestibular and cochlear hair cells
Inhibits glioma motility
Increases glioma invasion
Induces morphology changes in C6 glioma cells
Induced PLC/Ca2+ in C6 glioma cells
Essential for neuronal development/excitability in 
zebrafish
Spontaneous seizures in S1P2 null mice
Loss of vestibular function in S1P2 null mice 
S1P3
May inhibit neurite extension in PC12 cells
S1P4
Only expressed in lymphatic and hematopoietic tissues
S1P5
Stimulation of PLC-Ca2+ and PLD in C6 glioma
Inhibits oligodendrocyte progenitor migration
Induces process retraction and cell survival in 
oligodendroglial cells
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have  been  focused  on  isolated  cells  in  culture  (Table  A.1).  It  has  previously  been 
demonstrated that in PC12 cells  and dorsal  root ganglion (DRG) neurons,  NGF induces 
translocation of SphK1 to the plasma membrane . S1P thus causes activation of S1P1 leading 
to Rac activation and neurite extension. In addition, NGF downregulates S1P2 and S1P3, 
which leads to neurite retraction by activation of Rho . Evidence for the role of S1P in CNS 
neuroexcitability emerged from some observations of S1P2 knockout mice. It was noticed 
that  homozygous  knockout  mice  occasionally  exhibited  seizure  activity  characterized 
behaviorally by a 2-10 second wild running episode followed by a 15-60 second period of 
freezing .  These events  occurred only in  3-7 week old mice and were accompanied by 
changes in electrical activity of the brain . However, recent studies have demonstrated that 
S1P2 knockout mice are profoundly deaf from postnatal day 22 and display a progressive 
loss of vestibular function . 
S1P enhances the excitability of cultured rat DRG neurons that is likely mediated via 
S1P receptors, as blockade of G-protein signaling abrogated these effects of S1P . Moreover, 
S1P  generated  intracellularly  from ceramide  can  also  increase  neuronal  excitability  by 
mechanisms that are poorly understood . S1P was also recently shown to have two actions on 
glutamate secretion in  primary hippocampal  neurons: (i)  it  can act  as a secretagogue to 
trigger glutamate secretion and (ii) to potentiate depolarization evoked glutamate secretion . 
Depolarization-induced glutamate release  was dependent  on SphK1,  S1P formation,  and 
subsequent S1P1 activation. These findings indicate that S1P, through its autocrine action, 
facilitates glutamate secretion in hippocampal neurons and may be involved in mechanisms 
underlying regulation of synaptic transmission . Furthermore, neural stem/progenitor cells 
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migrate toward a damaged area of the CNS to reduce the damage. It was recently reported 
that S1P concentration in  the spinal cord was increased after  a contusion injury,  due to 
accumulation of microglia and reactive astrocytes in the injured area. Moreover, this locally 
increased S1P induced migration of transplanted neural  stem/progenitor cells  through its 
receptor S1P1 . 
S1P is also involved in growth and survival of oligodendrocytes , the myelinating 
cells of the CNS. The survival promoting effect of neuotrophin-3 (NT-3) on oligodendrocyte 
precursors was shown to be dependent on SphK1 and S1P itself was able to stimulate CREB 
phosphorylation, an important NT-3 survival signaling pathway . S1P5, which is exclusively 
expressed on oligodendrocytes and throughout their development, has different functions 
depending on the developmental stage.  It  mediates process retraction of oligodendrocyte 
precursors and promotes survival of mature oligodendrocytes . Moreover, activation of S1P5 
inhibits oligodendrocyte progenitor migration . S1P receptors are differentially modulated in 
oligodendrocyte progenitors by PDGF resulting in downregulation of S1P5 and upregulation 
of S1P1 .  Moreover,  S1P1 is  involved in PDGF-induced proliferation of oligodendrocyte 
progenitors.  Thus,  S1P1 and  S1P5 may have  different  functions  during  oligodendroglial 
development, and possibly during remyelination . 
Destruction of oligodendrocytes is a key pathological process in multiple sclerosis 
(MS).  The current therapies available  for MS utilize  an immunomodulatory approach to 
prevent T-cell- and macrophage-mediated destruction of brain-resident oligodendrocytes and 
axonal  loss.  Recently,  the  sphingosine  analogue,  FTY720  (Fingolimod),  was  shown  to 
significantly reduce relapse rates in MS patients and is currently in Phase III clinical trials . 
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FTY720  is  a  pro-drug  that  is  phosphorylated  in  vivo  by  SphK2  but  not  SphK1   to 
biologically active FTY720-phosphate (FTY720-P), a mimetic of S1P. FTY720-P binds to 
four of the five known S1P receptors, but not to S1P2. Although it is a S1P1 receptor agonist, 
it  has been shown to cause prolonged receptor downregulation . As S1P1 is required for 
lymphocytes to sense and move towards the S1P gradient between tissues and blood, its loss 
prevents egress of thymocytes and lymphocytes from secondary lymphoid tissues into the 
circulation  .  It  has  been  assumed  that  the  beneficial  effects  of  FTY720  result  from 
retardation of lymphocyte mobilization to sites of inflammation without an induction of a 
generalized state of immunosuppression. However, the mechanisms underlying the action of 
FTY720 in MS have not yet been definitively identified. For example, FTY720 has been 
shown to also have direct effects on oligodendrocyte progenitors . Treatment of these cells 
with  FTY720  causes  activation  of  ERK1/2  and  Akt,  accompanied  by  protection  from 
apoptosis . FTY720P also regulates oligodendrocyte progenitor differentiation into mature 
oligodendrocytes . However, FTY720 also arrested oligodendrocyte differentiation, an effect 
that was counteracted by NT-3, which not only enhanced the survival of oligodendrocyte 
progenitors induced by FTY720, but also stimulated their maturation . FTY720 also was 
recently  shown  to  induce  time-dependent  modulation  of  S1P  receptors  on  human 
oligodendrocyte progenitors with consequent functional responses that were directly relevant 
for the remyelination process . Altogether, these observations suggest that in addition to its 
immunosuppressive functions, FTY720 could also have a beneficial effect in MS by these 
direct actions on oligodendrocyte progenitors. However, the finding that FTY720 impedes 
the differentiation of these cells  raises the question of whether FTY720 therapy for MS 
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should include the use of differentiation-enhancing factors, such as NT-3 . This approach 
could ensure both protection of existing oligodendrocyte progenitor pools against immune-
mediated insults as well  as stimulation of remyelination by enhancing the maturation of 
these cells. 
Much less is known of the roles of S1P in other types of glial cells. Astrocytes, the 
major type of glial cell in the brain, are another target of FTY720 in the CNS as they express 
S1P1, S1P2, and S1P3 . FTY720-P as well as another agonist of S1P1, SEW2871, stimulate 
astrocyte migration . Astrocytes also express SphKs and can synthesize S1P and release it 
for autocrine/paracrine actions .  An interesting finding was that  fibroblast  growth factor 
(FGF), whose synthesis was earlier shown to be increased by S1P , can also stimulate S1P 
release from astroglial cells , suggesting a signaling amplification loop that further adds to 
the complexity of the relationship between growth factors and S1P. Moreover, S1P is present 
at high levels in blood and can enter the brain during CNS injury. Reactive astrogliosis, a 
prominent  component  of  CNS injury with  potentially  harmful  consequences,  could  also 
involve S1P-mediated proliferation of astrocytes . 
In  injured spinal  cords,  reactive  astrocytes  and microglia  around the injury sites 
colocalize to regions with high levels of S1P , suggesting that the accumulation of reactive 
astrocytes and microglia after spinal cord injury may be responsible for the increased level of 
S1P.  Only one study so far  has  examined functions of  S1P and the expression  of  S1P 
receptors in microglia, resident brain macrophages . While S1P1 S1P2, S1P3, and S1P5 were 
all  expressed by acutely isolated microglia,  S1P3 expression was lost after two weeks in 
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culture  .  In  addition,  stimulation  of  microglia  with  S1P  induced  the  release  of  TNFα, 
suggesting the potential involvement of S1P in CNS inflammation .
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A.4 PERSPECTIVES
Knowledge of SphKs and the functions of S1P has grown immensely over the past 
several years, and this trend will surely continue. It is truly amazing that so much has been 
written about  the functions  of  S1P,  yet  so little  is  still  known of  the regulation  of  the 
enzymes that determine its levels. It is a growing field, with important implications for future 
therapeutics  for  neurodegenerative  disorders,  particularly  MS.  Progress  in  developing 
specific agonists and antagonists of S1P receptors, as well as specific inhibitors of SphK1 
and SphK2 will provide the necessary tools to understand their functions and development of 
new approaches to target the S1P axis.
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